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Abstract 
Impairment of fetal oxygen levels and nutrient delivery contributes to fetal growth restriction 
(FGR), which affects 20% of pregnancies. Such cellular stress induces hepatic Insulin-like 
Growth Factor Binding Protein 1 (IGFBP1) phosphorylation, which sequesters Insulin-like 
Growth Factor 1 (IGF-I) and markedly reduces fetal growth signaling. IGFBP1 
hyperphosphoryaltion in hypoxia is mediated through the mTOR signaling pathway and 
through the Amino Acid Response (AAR) pathway during amino acid deprivation. Hypoxia 
stimulates upstream mTORC1 regulators, AMPK and REDD1 which are well-established 
upstream regulators of one of the two mTOR complexes, mTORC1. The molecular 
mechanisms by which upstream mTORC1-driven processes regulate IGFBP1 phosphorylation 
in hypoxia are unknown. We hypothesized that AMPK impacts IGFBP1 phosphorylation by 
modulating mTORC1 signaling due to hypoxia – a key factor in the development of reduced 
fetal growth in utero. Our results indicated that upregulation of AMPK phosphorylation at 
Thr172 via chemical activators leads to greater IGFBP1 phosphorylation. Additionally, we 
investigated the effects of combined hypoxia and amino acid deprivation (specifically leucine) 
on pIGFBP1 levels. We hypothesized that combined hypoxia and leucine deprivation results 
in greater IGFBP1 phosphorylation than either treatment alone, however we found that the 
combined conditions lead to IGFBP1 phosphorylation similar to leucine deprivation alone. The 
investigations in this study of nutrient sensing proteins (AMPK-MTORC1) and multiple 
cellular stressors (nutrient deprivation and hypoxia) mediating IGFBP1 hyperphosphorylation 
help provide greater insight of the underlying mechanisms regulating FGR. 
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Summary for lay-person 
An estimated 20% of all pregnancies are affected by fetal growth restriction (FGR), a condition 
characterized by improper nutrient flow to the developing fetus, usually resulting in infants 
with low birthweight.  The onset of FGR during pregnancy can also negatively impact physical 
and neurological health throughout childhood and even into adulthood. These children are 
disproportionately affected by learning disorders such as ADHD and are at a higher risk for 
the development of diabetes, obesity and cardiac diseases in later life. Thus, the effects of FGR 
have life-long health implications making better diagnosis and subsequent therapeutic 
intervention during pregnancy imperative.  
Current diagnostic methods aim to identify physical manifestations of disease through 
evaluation of physical markers of proper fetal growth such as fetal height and maternal weight, 
as well as using radiological techniques to visualize the developing baby. However, these 
methods often identify FGR symptoms late into pregnancy, when symptoms have fully 
manifested and are irreversible. Our study aims to help identify the onset of FGR earlier on, 
through the detection of a network of proteins and their signaling activity at the cellular level.  
The hepatic protein Insulin-like Growth Factor Binding Protein 1 has been highly associated 
with FGR and is known to mitigate specific protein pathways crucial to fetal growth, especially 
when phosphorylated.  
In this study we hypothesized that IGFBP1 protein and its’ phosphorylation is regulated 
through a network of proteins reliant on AMPK protein in low oxygen conditions, we also 
hypothesized that conditions of nutrient deprivation combined with low oxygen would amplify 
IGFBP phosphorylation and increase the levels of IGFBP1. We found that AMPK is among a 
network of several oxygen sensing proteins involved with increasing IGFBP1 protein and 
phosphorylation levels. We also found that conditions of low oxygen and nutrient restriction 
did not amplify the levels of IGFBP1 protein and phosphorylation levels greater than that 
observed when only one of the conditions is present. These findings help to further shed light 
about the network of proteins and conditions involved in manifesting FGR at cellular level and 
helps us to better understand the nature of the disease.  
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1 Introduction  
1.1 Fetal Growth Restriction 
Fetal Growth Restriction (FGR), also known as Intrauterine Growth Restriction (IUGR) is a 
growth disorder characterized by attenuation of fetal growth during pregnancy. The fetal 
growth potential is determined by a combination of fetal and maternal genetic factors as well 
as external and environmental factors.1 During pregnancy factors such as maternal diet, 
exercise, diseases, infections, air quality and even socioeconomic status have an important role 
in determining fetal growth.2 A crucial component in fetal development is the transfer of 
nutrients and gases from the mother to the fetus via the placenta.3,4 Abnormalities or 
complications in any of these areas can potentially lead to FGR. Deterioration in placental 
function during pregnancy limits the transfer of oxygen and nutrients to the fetus contributing 
to FGR.5 Conditions such as preeclampsia, poor nutrition, smoking, hypertension or blood 
disorders in the mother often result in placental insufficiency–often found concurrently with 
FGR.6 The consequences of FGR not only impair early development of the fetus but go on to 
produce life-long complications in the overall health of the individual such as learning 
disorders, higher prevalence of cardiac diseases, and obesity.7,8 
 
 
 
 
 
 
 
 
Figure 1: Factors contributing to FGR/IUGR. Factors such as diabetes, high blood pressure, 
infections, preeclampsia, chromosomal abnormalities, smoking and nutrition are a few of 
several contributing factors in the development of FGR/IUGR.31 
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1.2 Fetal Growth Restriction Diagnosis 
FGR affects 8-10% of all pregnancies and are often associated with higher rates of neonatal 
mortality and morbidities. Infants affected by FGR are identified based on birth weight below 
the 10th percentile for gestational age.1 However, it is often difficult to differentiate newborn 
infants afflicted with FGR with from Small for Gestational Age (SGA) newborn infants who 
often lack the physiological comorbidities associated with FGR infants. Therefore, other 
physical features in addition to weight must be considered.4 The FGR infants have been noted 
to have more pathological features such as asymmetry in parts of the body, especially in cranial 
skeletal structure. The limited transfer of nutrients to the fetus also leads to permanent 
alteration of gene expression in cells such as adipocytes, myocytes, pancreatic beta cells and 
hepatocytes. Such alterations in gene expression can vastly change metabolic and endocrine 
functions leading to greater risk of cardiac diseases, diabetes and obesity in adulthood.9 Infants 
born with FGR often grow up to be more susceptible to developmental and learning disorders 
during early years.6, 10 
Onset of the disease may be caused by a number of factors such maternal, fetal or placental 
factors. Reduced maternal-fetal nutrient and gas exchange as a consequence of placental 
defects is often one of the most critical and common factors contributing to FGR. Placental 
insufficiency is often diagnosed concurrently with FGR in affected fetuses. The attenuation of 
oxygen and nutrient supply lead to changes in metabolic proteins and gene expression prior to 
the physical manifestation of FGR. The changes in protein expression may occur as a result of 
the oxygen and nutrient stress or genetically predetermined factors, both leading to reduced 
growth signaling activity. This has been determined in the past through identification of 
nutrient sensing pathways which are downregulated as a result of the stressors such as Insulin-
like Growth Factor 1 Receptor (IGF1R) and Mechanistic Target of Rapamycin (MTOR) 
signaling cascade, crucial regulators of fetal growth.11 Conversely, cellular stress responsive 
signaling pathways are upregulated as a result of nutrient deficiency such as the Amino Acid 
Response (AAR) and Unfolded Protein Response (UPR) pathways.12 Investigation of these 
pathways and their role in the pathophysiology of FGR may provide greater insight in the 
detection and manifestation of the disease, allowing for the development for better medical 
interventions and therapeutics for FGR.9,13 
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Current methods of diagnosis primarily focus on identifying maternal risk factors such as blood 
sugar levels, potential infections, blood pressure, nutrient intake, maternal abdomen 
circumference, as well as determining fetal physical markers of development such as size and 
weight through sonographic evaluation.9 The flow of blood between the fetus and placenta is 
also monitored using uterine arterial Doppler evaluation of the umbilical artery. However, 
these methods can often lead to unclear understanding of the fetal growth level.14,15 In addition, 
physiological and metabolic changes in the fetus occur much earlier than the manifestation of 
the physical symptoms of FGR, making it crucial to find methods that can evaluate the onset 
of FGR symptoms prior to the manifestation of growth attenuation. Effects of early onset FGR 
are detectable at 34-week gestational age however changes in fetal protein and gene expression 
levels occur prior to that and are often irreversible even with interventions.16 In addition to the 
difficulty in establishing early intervention of FGR pregnancies, differentiation of FGR infants 
from small for gestational age infants (SGA) is often very difficult to decipher. Approximately 
70% of all SGA infants lack comorbidities found in FGR cases. These infants are often healthy 
but simply have lower body/mass index due to factors such as ethnicity, sex and genetics. Thus, 
these current markers of identification are largely qualitative and manifest beyond stages of 
effective intervention, making the need for effective pathophysiological analysis earlier in the 
onset of FGR.16  
1.3 IGF1R, IGF1 and IGFBP1 signaling cascade 
The Insulin-like Growth Factor (IGF) system of proteins, receptors and ligands are crucial to 
mediating growth signaling activity and facilitating proper fetal development. The IGF system 
consists of three different receptors: Insulin-like Growth Factor I Receptor (IGF-IR), Insulin 
Receptor (IR) and Mannose-6-phosphate (M6P) / Insulin-like Growth Factor II Receptor (IGF-
IIR).17 Although all three receptors are important facilitators of metabolic and mitogenic 
activity, the IGF-IR complex is of particular interest to us in this study as it facilitates mitogenic 
activity through IGF-I and IGF-II ligand binding, which is significantly crucial to fetal 
development.17  The IR and M6P/IGF-IIR receptor complexes also bind to IGF-I and IGF-II 
ligands but to a much lower affinity than IGF-IR.  As their name suggests, IR has a strong 
affinity for insulin-binding, while M6P/IGF-IIR receptor has a strong affinity for mannose-6-
phosphates as ligands. The Insulin Receptor helps mediate mitogenic activities via binding to 
IGF-II, progressing the cell from G0/G1 to S and G2/M phases of the cell cycle. The M6P/IGF-
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IIR receptor mainly targets M6P residues on newly synthesized lysosomal enzymes from the 
Golgi apparatus to the lysosomes, ensuring delivery of extracellular lysosomal enzymes to the 
appropriate cell compartment. Additionally, M6P/IGF-IIR receptor also binds to M6P residues 
on IGFs but has a much greater affinity for IGF-II than IGF-I. The M6P/IGF-IIR plays a crucial 
role in the internalization and degradation of IGF-II, making it an important process in limiting 
growth, and especially of tumorigenic growth. 17 
Both IGF-I and IGF-II ligands share strong similarities in sequence with insulin, as well as 
structural similarities with proinsulin.18,19 Although both IGF-I and II are important regulators 
of fetal growth, IGF-II plays crucial role during early gestational age in neural and postnatal 
development. IGF-I however plays an important from mid to late gestational age. 17  Both IGF-
I and II bind to strongly to IGF-IR initiating mitogenic signaling and proliferation.  IGF-I is 
also found to be correlated in low concentrations in fetal umbilical cord in growth restricted 
infants and conversely in higher concentration in healthy infants. Recent studies have also 
implicated human Growth Hormone (GH) in mediating growth globally similar to IGF-I. Both 
proteins are important in endocrine signaling, promoting the growth globally, as well as in an 
autocrine and paracrine manner, promoting growth of the liver. 17 While both IGF1 and GH 
mediate postnatal development, IGF1 has been shown to demonstrate similar effects as GH 
and are secreted at higher concentrations than GH, which are present in low levels. Defects in 
IGF-I structure lead to more severe growth restriction while GH defects lead to mild growth 
restriction. This further indicates the importance of the role of IGF-I ligand in IGF-IR 
activation as well as promotion of overall growth in fetuses. 18,19, 20 
The bioavailability of IGF-I ligand is impacted by the presence of insulin-like growth factor 
binding proteins (IGFBP) which bind to IGF-I, extending IGF-I half-life and sequestering it 
from circulation. The IGF system consists of six different IGFBPs (numbered 1 to 6) which 
are expressed in various tissues and organs throughout the body.21,22 All IGFBPs contain great 
structural homology specifically around the N and C terminus regions, and contain a flexible 
linker domain common to all IGFBPs.23 Mutagenic studies of IGFBP1 gene corelating to the 
N-terminuses lead to the lack of IGFBP1-IGF-I binding, suggesting that the N-terminus 
structure of IGFBP1 is crucial for binding. 21,22,23 The importance of the IGFBP1 N-terminus 
in IGF-I was initially predicted based on nuclear magnetic resonance studies of the region, 
however site-directed mutagenesis of the region further clarified the important role the N-
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terminus region has in IGFBP1-IGF-I binding.   Though IGFBPs can bind to IGF-Is, they have 
varying effects depending on the type of IGFBP binding to IGF-I and the location of where the 
binding is occurring. 21,22,20 
The IGFBPs can be found circulating globally and locally in specific tissues. In circulation, 
IGFBPs act as transport proteins carrying IGF-Is, this is often the case with IGFBP3.17 
However, in local tissues, IGFBPs can act as IGF1 regulators, binding to them and sequestering 
them from circulation. 17,21,22,20 Other IGFBPs can even act independently of the IGF-IR-IGF-
I system. The circulating levels of some IGFBPs increase in response to cellular or nutrient 
stress. Such is the case for IGFBP1 which increases in response to low oxygen, amino acids 
and increased endoplasmic reticulum stress; this effect on IGFBP1 can be most prominently 
observed in hepatocytes. The increased levels of IGFBPs in the cell bind to the IGF-Is, 
mitigating IGF-IR signaling activity, impeding the cell growth and proliferation processes. 16,24 
 
 
 
 
 
  
 
 
Figure 2: IGF-I-IGF-IR and IGF-I-IGFBP1 binding. IGF-I binds to IGF-IR activating 
growth signaling cascade, however in the presence of IGFBP1, IGF-I-IGFBP1 binding 
sequesters IGF-I bioavailability, mitigating the IGF-IR signaling cascade.25 
Often the obstruction of vascular nutrient and gas exchange from maternal blood to the fetus 
results in conditions of lowered fetal oxygen levels (hypoxia) and amino acid levels in FGR. 
These nutrient-deprived conditions upregulate secretion and phosphorylation of IGFBP1 in the 
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fetal liver- the main site of IGFBP1 expression during fetal development. Although other 
IGFBP’s, such as IGFBP3, are also expressed in the liver, IGFBP1 has the most pronounced 
expression and upregulation in response to hypoxia, starvation and cellular stress.26 The fetal 
liver  mediates crucial metabolic and physiological functions in early fetal development.16, 25 
The conditions of hypoxia and nutrient deprivation result in increased phosphorylation at 
several Serine residues (Ser 169, 119, 101, 98) in IGFBP1. 16 Currently, we are able to detect 
phosphorylation changes on Ser 169, 119 and 101 through immunoblot analysis through the 
use and development of customized antibodies targeted for these sites.27 Various types of 
cellular stress such as hypoxia, nutrient deprivation and even drugs such as rapamycin has 
varying degrees of change in the phosphorylation levels at each site.18 However, the overall 
increase in IGFBP1phosphorylation results in greater IGFBP1-IGF-I binding affinity. At 
healthy, physiological oxygen levels (normoxia), IGFBP1 phosphorylation can lead to a 6-8-
fold increase in IGFBP1-IGF-I binding affinity. 13,16 Alternatively, hypoxia leads to greater 
phosphorylation of IGFBP1 protein, which can lead to a 200-300-fold increase in IGFBP1-
IGF-I binding affinity. 13,16  The increased IGFBP1-IGF-I binding affinity during cellular stress 
and nutrient deprivations leads to reduced IGF-I bioavailability, attenuating IGF-IR signaling 
and subsequently fetal growth. 13,16, 25 
 
 
 
 
 
 
Figure 3: Phosphorylation of IGFBP1.  Phosphorylation of IGFBP1 leads to increase in 
IGFBP1-IGF-I binding affinity in normoxia (6-8-fold) and hypoxia (200-300-fold). 13,16, 25 
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1.4 Overview of nutrient sensing pathways regulating IGFBP1 
secretion and phosphorylation 
The biomolecular mechanisms mediating IGFBP1 phosphorylation during FGR is complex 
involving numerus pathways. Some of these pathways such as the AAR and mTOR signaling 
pathway have been shown to effectively regulate IGFBP phosphorylation during nutritional 
deprivation. In addition, the AAR and MTOR pathways overlap with the UPR signaling, 
indicating that growth attenuation via IGFBP1 phosphorylation in cellular stress or nutrient 
deprivation mediates a global response in cells.  Previous studies in our lab indicated that 
hypoxia mediates IGFBP1 secretion and phosphorylation via down regulation of MTOR 
complexes in human hepatoma cells (HepG2).18 We also determined that amino acid 
deprivation, specifically leucine deprivation, leads to increased IGFBP1 secretion and 
phosphorylation via upregulation of AAR pathway.19 Current studies in literature indicate that 
the UPR pathway proteins may be linked to MTOR downregulation and AAR upregulation 
during cellular stress.28 However, the role of UPR pathway in regulation of IGFBP1 
phosphorylation is unclear. 28,29,30 Additionally, the exact mechanism of how upstream MTOR 
regulators mediate hypoxic signaling to increase in IGFBP1 secretion or phosphorylation is 
also unclear.31 The downregulation of MTOR is indicated to be mediated through complex 
sequence of events through hypoxia sensing inducible factors (HIFs) and other proteins such 
as adenosine monophosphate kinase (AMPK) and DNA damage inducible transcription factor 
4 (DDIT4/REDD1).31,32 The role of HIF, AMPK and REDD1 in regulation of 
IGFBP1secretion and phosphorylation requires greater investigation.32,33,34  
Overall, the metabolic factors contributing to fetal growth restriction in multifactorial. Several 
pathways such as MTOR, AAR and UPR collectively contribute to IGFBP1 
hyperphosphorylation and subsequently reducing IGF1 bioavailability and sequestering 
IGF1R activity – a crucial signaling pathway in promoting fetal growth. Our hope is that by 
closely examining the protein activity contributing to IGFBP1 hyperphosphorylation, we may 
potentially pave the way to better able to identify the metabolic profile associated with fetal 
growth restriction and subsequently better prognosis of the disease. 
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Figure 4: Nutrient sensing pathways mediating IGFBP1 phosphorylation. The MTOR, AAR 
and UPR pathways respond to nutritional deprivation and cellular stress, leading to an upregulation 
of IGFBP1 phosphorylation. In this research study we examine (1) the relationship between AMPK 
activation and IGFBP1 hyperphosphorylation in hypoxia, as well as (2) the impact of combining 
conditions of hypoxia and amino acid deprivation on IGFBP1 hyperphosphorylation. 
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Figure 5: Overlap in nutrient sensing pathways mediating IGFBP1 phosphorylation. The 
MTOR, AAR and UPR pathways have significant overlap when mediating IGFBP1 
phosphorylation in response to nutritional deprivation and cellular stress.  
1.5 MTOR pathway 
The mammalian target of rapamycin (MTOR), also known as the mechanistic target of 
rapamycin is a serine/threonine kinase that is a major growth and proliferation mediating 
signaling pathway in human cells. MTOR is a highly sensitive nutrient sensing kinase that is 
affected by cellular energy levels, nutrient deprivation, oxygen and cellular stress. The MTOR 
complex is comprised of 2 subunits MTOR complex 1(C1) and 2 (C2).18, 35  MTORC1 is 
comprised of 5 different complexes, with MTOR as the main complex, a regulatory associated 
protein of MTOR (Raptor), mammalian lethal with SEC13 protein 8 (mLST8) and a Proline-
rich AKT1 substrate 40 and DEP domain-containing mTOR-interacting protein (DEPTOR) 
component. The last two are non-core components. MTORC2 is comprised of more than 5 
different complexes as well, and like MTORC1, C2 also has MTOR is as the main complex.11, 
18, 36 MTORC2 also contains a rapamycin-insensitive companion of MTOR (RICTOR), an 
MLST8 (GbL) component, a DEPTOR component. MTORC2 has unique components such as 
mammalian stress-activated protein kinase interacting protein 1 (mSin1), Protor ½, Telomere 
length regulation protein 2 and Tti1.35 
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Since MTOR is essentially a kinase that is affected by cellular conditions in the promotion of 
growth, several different downstream proteins are activated by the MTOR kinase in response 
to those conditions. Past studies have shown that inhibition of MTOR complexes leads to 
reduced cell growth and size. The MTOR complexes play an important role in cell autophagy, 
nutrient metabolism, ribosomal activity, and subsequently mRNA translation. The relative 
activity of the MTORC1 kinase has been well established through the evaluation of 
downstream effectors the Eukaryotic translation initiation factor 4E-binding protein 1 (4E-
BP1) and p70S6 kinase (p70-S6k or S6k). 35,36   The phosphorylation of 4E-BP1 and S6k are 
upregulated in response to increased MTORC1 activity due to factors such as nutrition and 
oxygen levels. Subsequently, they are downregulated in the absence of nutrition and oxygen. 
The inhibition of upstream MTORC1 negative regulator Tuberous Sclerosis Complex 2 
(TSC2) has been shown to upregulate MTORC1 downstream activity but not MTORC2 
activity. 35,36,37 The MTORC2 activity is observed through the phosphorylation of downstream 
proteins Protein Kinase C alpha (PKC alpha), Serum and Glucocorticoid-regulated Kinase 1 
(SGK1) Protein Kinase B (also known as Akt). Akt activity is prominently downregulated in 
response to MTORC2 inhibition during cellular stress.38 
The activation of downstream functional readouts of MTORC1/2 lead to the promotion several 
growth promoting pathways. S6k activation leads to increased protein translation of ribosomal 
proteins and also increase self-phosphorylation of S6k. Phosphorylation of 4E-BP1 via 
MTORC1 functions to promote global protein synthesis.11 When not activated 4E-BP1 binds 
to the eukaryotic translation initiation factor 4E (eIF4E) however, phosphorylation of 4E-BP1 
at Thr70 by mTORC1 prevents 4E-BP1 from binding eIF4E, allowing it to promote cap-
dependent translation of proteins. In this way, active mTORC1 signaling is able to promote 
cell growth through specific pathways via S6K phosphorylation, as well as broader scale 
changes to protein synthesis via 4E-BP1 phosphorylation.11,39 MTORC2 functions are more 
elusive than MTORC1. MTORC2 functions to upregulate cellular growth, survival and 
proliferation, as well as metabolism. 36 Additionally, MTORC2 plays an important role in 
regulation of cellular actin cytoskeleton.  The activation of Akt is mediated through MTORC1 
through phosphorylation at Ser473. 36  The activation of Akt allows for activation of several 
downstream proteins in facilitating gene expression of metabolic genes, cell-cycle arrest, and 
death.38   
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Past studies in our lab indicated that hypoxia mediated downregulation of MTORC1 and 2 
leads to greater IGFBP1 phosphorylation.18 However, the regulation of upstream MTORC1 
negative regulator TSC1/2 via AMP-Activated Kinase (AMPK) and DNA Damage Response 
1/DNA Damage Inducible Transcription Factor 4 (REDD1/DDIT4) in hypoxic conditions need 
to be further investigated.40 
 
Figure 6: Components of MTORC1 and MTORC2. The MTOR complexes are comprised 
of several units that together regulate and activate different growth and proliferative activities 
in the cell.36   
1.6 AMPK mediated downregulation of MTOR 
Cellular stress such as low oxygen levels (hypoxia) activates a diverse profile of proteins and 
enzymes that relay growth attenuation signaling in the cell. Our previous studies indicated the 
MTOR complexes to be a crucial mediator of growth attenuation. Hypoxic conditions activate 
a series of upstream MTOR modulators that lead to MTORC1 attenuation, these upstream 
MTORC1 regulators are known as AMP-Activated Kinase (AMPK) and DNA Damage 
Response 1/DNA Damage Inducible Transcription Factor 4 (REDD1/DDIT4). Both AMPK 
and REDD1  are activated in response to cellular stress.41,42,32 The secretion of REDD1 is 
increased in hypoxia in a Hypoxia Inducible Factor 1 alpha (HIF1a) dependent manner.40  The 
phosphorylation of AMPK is increased in response to hypoxia, due to changes in the AMP to 
RTP ratio. Both AMPK and REDD1 converge on the activation of MTORC1 negative 
regulator TSC1/2.43,44  REDD1 activates TSC1/2 in a parallel and AMPK-independent manner. 
However, unlike AMPK that responds to cellular energy levels, REDD1 is largely activated in 
hypoxic conditions through hypoxia sensing molecules such as Hif1a. 31,45 Conversely AMPK 
is activated by several different nutrient activated proteins. In this study we will examine the 
role AMPK in MTORC1 attenuation in hypoxia. 
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There are twelve different types of AMPK in mammals that are found in a tissue specific 
manner.46 These proteins are regulated allosterically through competitive binding and possibly 
post-translational modifications, however, the exact activity of the various types of AMPK or 
factors that affect the localization of the protein are not fully understood. Activation of AMPK 
is thought to be mediated when allosteric binding to the AMPK gamma subunit allows for 
phosphorylation of the Thr172 residue on the subunit. Phosphorylation of AMPK at Thr172 is 
upregulated in conditions of low energy in tissues, which leads to an upregulation of Adenosine 
Monophosphate (AMP) to Adenosine diphosphate (ADP) ratio. 47  AMPK phosphorylation in 
these conditions is mediated through upstream AMPK kinase (AMPKK).39 Various proteins, 
enzymes and even chemicals have been implicated to activate, as well as deactivate AMPK in 
response to cellular stress and nutrition levels.  
Known activators of AMPK are Liver Kinase B1 (LKB1), Calcium/Calmodulin-dependent 
protein kinase 2 (CAMKK2), TGF𝛽-activated kinase 1 (TAK1), as well as AMPKK. 
Activation of AMPK can be mediated through chemicals such as Aminoimidazole-4-
carboxamide ribonucleotide (AICAR) which is acts as an AMP analog. Sensing an 
upregulation of the AMP analog AICAR, AMPK is phosphorylated by AMPKK. In addition, 
AICAR is a chemical intermediate in the generation of Inosine Monophosphate (IMP), an 
important step in purine metabolism, thus, AICAR is a more natural stimulator of AMPK.48 
Aside from AICAR, Acetyl Salicylic Acid (ASA) or commercially known as Aspirin, has been 
shown to activate AMPK signaling pathway in various models.32,47 ASA is converted into its 
active form salicylate partially in low pH found in the stomach but more so by non-specific 
esterase found in hepatic tissue. ASA is able to activate AMPK by directly binding to the 
protein to cause inhibit dephosphorylation of AMPK activation site at Thr172.49 Activation of 
AMPK is one of the  pathways alongside REDD1 that can lead to activation of TSC1/2. The 
activation of TSC1/2 leads to inhibition of MTORC1 and subsequently attenuation of global 
cellular growth and proliferation.50 AMPK is also known to directly inhibit MTORC2, leading 
to an overall attenuation of growth signaling activity. 40,43  
Proteins known to promote AMPK dephosphorylation are Protein Phosphatase 2A (PP2A), 
Protein Phosphatase 2C (PP2C) and Mg2+/Mn2+ dependent protein phosphatase 1E (PPM1E).47 
As well, the compound Dorsomorphin/Compound C has also been shown to potentially 
attenuate AMPK phosphorylation in hepatocytes.51 In human hepatocytes, downregulation of 
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AMPK may lead to attenuation of TSC1/2 complex, an MTORC1 inhibitors. Reduced TSC1/2 
activity may  increase MTORC1 signaling activity and subsequently increased growth 
signaling activity.43 Although the role of  AMPK  as an upstream MTORC1 regulator has been 
established,  the greater role of AMPK in affecting IGFBP1 phosphorylation during cellular 
stress has yet to be investigated. 50, 52 
 
 
 
 
 
 
Figure 7: Activation of AMPK via salicylate and AICAR. Salicylate activates AMPK via 
binding at the b1 subunit of the protein, while AICAR acts as an AMP analog activates AMPK 
via upregulation of the AMP to ATP ratio. 47  
1.7 Amino acid deprivation 
There are 20 amino acids, of which nine are essential amino acids (EAAs). These are leucine, 
isoleucine, valine, lysine, threonine, tryptophan, phenylalanine, methionine, histidine.19  These 
amino acids are crucial to growth, development and maintenance of bodily functions. 
However, EAAs are not synthesized inside the human and must be acquired externally.19,53   
Excess EAAs however are not stored and are expelled from the body. Therefore, an adequate 
and continuous supply of EAAs are essential to the development of a healthy fetus 
(fetogenesis).54,53 During fetal development, the supply of EAAs are transported from the 
maternal blood to the fetus via the placenta. Often FGR pregnancies have reduction trans-
placental EAA transport. Down-regulation of the expression of placental amino acid 
transporters such as System L (leucine) transporter, Taurine transporter (TAUT), and System 
A transporter lead reduced fetal EAA levels in FGR.55 Damage or abnormalities to the placenta 
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lead to reduced fetal access to EAAs, in addition to maternal malnutrition which can also 
reduce maternal and fetal supply of EAAs.55 In cases where some form of placental dysfunction 
reduces limits the EAA supply, the levels of EAA in maternal blood increases whilst fetal EAA 
levels remain low. 55   
The reduced fetal amino acid availability leads to a range of problems in fetal development.12 
Amino acid deprivation studied on animal models indicated that maladaptation to the limited 
nutrition manifests as quickly as 48 hours, resulting in attenuation of growth. 12 In addition, 
reduced maternal nutritional intake or fasting, especially in the third trimester can lead to 
impaired gluconeogenesis. The severe need to provide energy in fetus impairs process 
mediating fetal growth. Reduction in placental amino acid transfer increases fetal protein 
catabolism, concentrations of certain fetal tissue amino acids increase in human FGR. Several 
studies have indicated that the fetal response to amino acid deprivation leads to long term 
repercussions on offspring health in addition to attenuation of fetal growth. 12  
In an experimental model using rats for investigating the long-term effects of FGR, nutrient 
restricted pregnant rats showed significantly lower levels of circulating essential branched 
chain amino acids. This led to the onset of FGR in the off-springs, which had severe glucose 
intolerance and atherosclerosis in their adult life.28 In human FGR cases, in approximately 70-
80% of FGR infants, metabolic stress due to amino acid deprivation and subsequently low 
energy supply causes the fetus to prioritize preservation of the functions of vital organs such 
as the heart, brain and placenta whilst compromising of the full maturation of other organs.19,56 
This frequently leads to FGR infants that are typically born with asymmetrical growth and 
larger head to body mass ratios. 56  Additionally, maturation of several fetal organs, even the 
brain is also compromised leading compromised function in later life. 15,57,58 
1.8 Amino Acid Response pathway 
The amino acid response (AAR) pathway is activated in response to decreased essential amino 
acid concentrations and is a cellular stress response mechanism in mammalian cells.12 The 
AAR pathway is a part of the integrated stress response pathways (ISR) that are comprised of 
several proteins that relay and activate stress signaling.19 When the transfer of nutrients from 
the maternal blood to fetus placenta is obstructed, a series of stress responsive pathways are 
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triggered resulting in attenuation of fetal growth. These conditions elicit an activation of amino 
acid response pathway.54,59 The amino acid response is an evolutionarily conserved mechanism 
that can be observed in various species in the manifestation of FGR.  
Activation of the amino acid response starts with the phosphorylation of general control 
nonderepressible 2 (GCN2) protein, which then leads to the phosphorylation of eukaryotic 
translation initiation factor 2 A (EIF2A).60,61 The upregulation of EIF2A leads to the increased 
expression of activating transcription factor 4 (ATF4).62 Conditions of amino acid starvation 
promote the accumulation of uncharged tRNA molecules. These uncharged tRNA molecules 
are detected and sensed by GCN2. The tRNA binds to GCN2 initiating the AAR sequence 
signaling activity.63,64 The binding of uncharged tRNA molecules to GCN2 leads to 
dimerization of the latter, and subsequent autophosphorylation at Thr898.65 GCN2 is 
serine/threonine kinase and is one of four different kinases that lead to the activation of the 
second step in the AAR, activation of EIF2A.53 
Although EIF2A is the only identified downstream target for GCN2, EIF2A is phosphorylated 
by the Unfolded Protein Response (UPR) pathway protein PKR-like endoplasmic reticulum 
(ER) kinase (PERK).30, 66 The UPR pathway is activated in response to unfolded proteins, 
endoplasmic reticulum stress and even hypoxia. Additionally, EIF2A is activated by heme-
regulated inhibitor kinase (HRI) in response to fluctuation in hemoglobin levels, and double-
stranded RNA-activated protein kinase (PKR) in response to viral infections. Although all four 
kinases activate EIF2A, the downstream effects on proteins and gene expression is varied 
depending the kinase that phosphorylates EIF2A.67,68 Activation of EIF2A via AAR and UPR 
both lead to the increased expression of Activating Transcription Factor 4 (ATF4), that 
mediates changes and global translation and gene expression. However, ATF4 has varied 
downstream affects when activated by AAR and UPR.62, 69 The upregulation of ATF4 protein 
expression allows ATF4 to allow for the transcription of genes that promote growth 
attenuation. 
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Figure 8: Amino acid deprivation activates the AAR pathway signaling. The AAR 
pathway signal is relayed through phosphorylation of GCN2, EIF2a and increased expression 
of ATF4 which promotes expression of AAR genes.54  
Previous studies in our lab indicated that the AAR pathway can be triggered by depriving 
HepG2 cells of branched amino acid leucine.13,19 Conditions of leucine deprivation resulted in 
hyperphosphorylation of IGFBP1 via the upregulation AAR signaling proteins. However, 
disruption in the transfer of nutrients through the placenta results in fetal deprivation of both 
amino acids and oxygen. 13,19 The condition of hypoxia and amino acid deprivation are often 
concurrently present and have yet to be investigated.   
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1.9 Rationale, Hypotheses and Objectives for overall study 
The condition of Fetal Growth Restriction induces changes the drastically alter gene and 
protein expression. Our goal is to investigate this phenomenon using HepG2 cells as a model 
for fetal hepatocyte – a major site of hormone and metabolite secretion essential to fetal 
development. We sectioned this study into two parts – firstly, (1) investigating the role of 
upstream MTOR regulator AMPK in mediating IGFBP1 hyperphosphorylation in hypoxia; 
secondly, (2) we investigate the novel effect multiple stressors (hypoxia and amino acid 
deprivation) have on protein pathways that we have identified in previous studies as 
contributors to IGFBP1 hyperphosphorylation. The reason we investigate both protein 
regulators and cellular stress stimuli in mediating IGFBP1 phosphorylation, is because both of 
these factors contribute to the inhibition of cellular growth. Although we look deeper into the 
rationale for these aspects separately in the sections below (Section 1.9.1 for AMPK and 
Section 1.9.2 for combined stressors) our overall goal is to understand the varying metabolic 
changes occurring during fetal growth restriction, by studying the IGBP1 mediated attenuation 
of IGF1-IGF1R activity. We hypothesize that growth attenuation is a result of multifactorial 
cellular stress, activating several proteins upstream of major growth signaling pathways such 
as MTOR and AAR, resulting in a diverse metabolic profile contributing towards IGFBP1 
hyperphosphorylation and growth attenuation in large. 
1.9.1 Rationale, Hypothesis and Objectives for AMPK modulation 
Rationale: Previous studies have indicated that hypoxic conditions increase AMPK 
phosphorylation at Thr172 and upregulate REDD1 total protein,  which subsequently lead to 
MTORC1 downregulation through the activation of MTORC1-inhibitor TSC1/2.35 Previous 
studies in our lab indicated that MTOR inhibition is a key step in promoting IGFBP1 
hyperphosphorylation.18 However, it is unknown if AMPK modulation via hypoxia or 
chemical activators can directly impact IGFBP1 hyperphosphorylation via inhibition of the 
MTOR pathway.  
A detailed schematic of the proposed pathway is shown in Figure 9 in conditions of normoxia 
(left) and hypoxia (right). 
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Hypothesis: Hypoxic induction of AMPK increases IGFBP1 phosphorylation via negative 
regulation of MTORC1 in vitro using HepG2 cells as a model for fetal hepatocytes. 
Aim: In this study, I will determine the upstream regulation of MTORC1 via AMPK in 
mediating IGFBP1 phosphorylation during hypoxia. 
Objectives:  
  (1)  Determine if AMPK or REDD1 is stimulated during hypoxia.   
(2) Determine if AMPK modulation of MTORC1 in hypoxia can induce IGFBP1 
phosphorylation. 
 
 
 
 
 
 
Figure 9: Schematic for hypothesized AMPK mediated upregulation of IGFBP1 
hyperphosphorylation via downregulation of MTORC1. We hypothesize that hypoxic 
signaling relays AMPK mediated downregulation of MTORC1 and subsequently leading to 
downregulation of 4E-BP1 phosphorylation and p70-S6K (S6K) phosphorylation. All of these 
steps may collectively be leading to an increase of IGFBP1 phosphorylation, a major protein in 
facilitating fetal growth restriction. 
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1.9.2 Rationale, Hypothesis and Objectives for combined hypoxia 
and leucine deprivation treatment 
Rationale: Condition of hypoxia elicit IGFBP1 hyperphosphorylation via downregulation of 
MTOR,18 while conditions of nutrient deprivation (specifically leucine) elicit IGFBP1 
hyperphosphorylation through the upregulation of AAR pathway.19  However, these conditions 
are often found simultaneously in FGR and the proteomic activity in combined conditions of 
hypoxia with leucine deprivation has yet to be investigated. 13,19 
Hypothesis: Hypoxia mediated downregulation of MTOR and nutrient deprivation mediated 
upregulation of AAR pathways occur simultaneously during combined conditions of hypoxia 
with nutrient deprivation in vitro using HepG2 cells. The combined conditions hypoxia with 
leucine deprivation lead to greater levels of IGFBP1 phosphorylation than either treatment 
alone due to the activation of cellular stress response on IGFBP1 hyperphosphorylation 
through both MTOR and AAR pathways. 
Aim: Determine regulation of IGFBP1 phosphorylation via MTOR and AAR in combined 
conditions of hypoxia and amino acid deprivation. 
Objectives: 
(1) Determine the levels of IGFBP1 phosphorylation in combined hypoxia with leucine 
deprivation in comparison to either hypoxia or leucine deprivation. 
(2) Determine the activity levels of MTOR and AAR pathways in combined hypoxia 
with leucine deprivation in comparison to either hypoxia or leucine deprivation. 
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1.9.3 Rationale for using HepG2 cell model 
Although IGFBP1 can be found circulating in the blood and in various parts of the body, it is 
highly expressed in the liver during growth restriction.17,21, During fetal development the liver 
acts major metabolic driver of growth through the secretion of various growth hormones and 
proteins such as IGF-I. For that reason, our goal was to select a model based on the human 
fetal liver. The HepG2 cells exhibit protein characteristics and gene expression patterns similar 
to primary human fetal hepatocytes are widely used as a model for fetal hepatocytes.70,71 Like 
fetal hepatocytes, HepG2 cells also mainly express fetal isoenzymes of aldolase, pyruvate 
kinase, with limited cell surface receptor for asialoglycoproteins.72 Previous studies in our lab 
indicated HepG2 cells to exhibit similar patterns of IGFBP1 phosphorylation and MTOR 
downregulation during nutrient deprivation as fetal baboon primary hepatocytes.16 Therefore 
HepG2 cells were highly preferred for this study.  
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2 Methods  
2.1 Cell Culture 
In this study, human hepatocellular carcinoma cells (HepG2) were used as a model for fetal 
hepatocytes. The HepG2 (American Type Cell Culture Collection, Manassas, VA) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) with nutrient mixture F-12 
(DMEM/F-12) supplemented with 10% fetal bovine serum (FBS) (Invitrogen Corp, Carlsbad, 
CA) and placed in an incubator at 37°C in 20% O2 and 5% CO2. The HepG2 cells were grown 
to 80% confluence in T-75 flasks (Invitrogen) prior to being plated in 6-well polystyrene 
culture dishes (Invitrogen) using 3 mL of 0.5% trypsin-EDTA of 1:10 dilution (Life 
Technologies, Carlsbad, CA) for 5-8 mins at 37°C. Cells were then re-suspended in 10% FBS, 
DMEM/F12 media to achieve a concentration of 3x105 cells/mL . A total of 2 mL of the cell 
suspension was aliquoted to each well in the 6-well polystyrene culture dishes and placed in 
an incubator at 37°C in 20% O2 and 5% CO2 for 24 hours, after which the cells were starved 
in either serum-free DMEM/F12 or 2% FBS DMEM/F12 overnight. After starvation, cells 
were treated with various treatments and subsequently placed back in the incubator at 37°C in 
20% O2 and 5% CO2 for 24 hours. 
2.2 Hypoxia Treatment 
HepG2 cells starved with 2% FBS with DMEM/F12 overnight were placed in a modular semi-
sealed chamber (Billups-Rothenberg Inc., Del Mar, CA) that was flushed with 1% O2 and 5% 
CO2 for 15 mins to stimulate hypoxia. The hypoxia flushed chamber with HepG2 cells was 
subsequently sealed to prevent any gases from leaving or entering. The chamber was then 
placed on a gentle shaker in 37°C for 24 hrs. At the same time, another set of HepG2 cells 
starved with 2% FBS with DMEM/F12 overnight, were placed in 20% O2 and 5% CO2 for 24 
hours to stimulate conditions of normoxia. 
In past studies in our lab, the oxygen content in the hypoxic chamber was verified to be 1% O2 
at 12 hour intervals using a Hudson 5590 Oxygen Monitor (Hudson, Ventronics Division, 
Temecula, CA).13 Additionally, the pH and partial pressure of O2 and CO2 were monitored 
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using an ABL700 series blood gas analyzer (Radiometer, Copenhagen, Denmark). The pO2 
was determined to be 43.3 torr or 1.53 mm Hg for 1% O2 and 133.3 torr or 7.36 mm Hg for 
20% O2 at the end of the hypoxia treatment period.13,73 The pH level was determined to be 
between 4.5 and 5.5, while decreases between 0.7 to 0.9 were observed in hypoxic treatments.13 
The pCO2 remained stable between control and hypoxic treatments.13 
2.3 Optimization of AMPK activation and inhibition 
Modulation of AMPK was mediated through select activators (acetylsalicylic acid/ASA and 
5-aminoimidazole-4-carboxamide ribonucleotide, (Caymen Chemicals, Ann Arbor, MI)) and 
inhibitor (Dorsomorphin (Caymen Chemicals, Ann Arbor, MI)). In order to determine the 
optimal concentration of AICAR, ASA and Dorsomorphin for the treatment of HepG2 cells, a 
dose response experiment was conducted for each chemical. Concentrations of 3 and 5 uM 
acetylsalicylic acid were tested for optimal levels of IGFBP1 secretion and phosphorylation. 
Concentrations of 0.10, 0.25, 0.50, 0.75 and 1.00 mM was tested for AICAR. And lastly 
concentrations of 1.0, 2.5, 4.0, 5.0 and 10 uM were tested for Dorsomorphin.  
HepG2 cells were treated using optimal concentrations of 15.5 mM for ASA, 0.25 uM for 
AICAR and 2.5 uM for Dorsomorphin in 2% FBS with DMEM/F12 for 24 hours, following 
overnight starvation in 2% FBS with DMEM/F12. The cells were either treated in either 
normoxia or hypoxia as described in Section 2.2.  After 24 hours of treatment, cell media and 
cell lysate were collected as described in Section 2.5.  
Table 1. Activators and inhibitors of AMPK 
 
2.4 Leucine deprivation with hypoxia 
Special DMEM/F-12 media selectively deprived of essential amino acids leucine, methionine, 
lysine, glutamine, as well as various salts (Sigma-Aldrich Corp., St. Louis, MO) was used for 
the preparation of Leucine 450 mM media. All essential amino acids, except leucine, were 
AMPK modulation
Activators Inhibitors
Acetyl salicylic acid (ASA) Dorsomorphin (Compound C)
AICAR
15
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added to the special DMEM/F-12 media to levels normally found in regular DMEM/F-12 
media. Biological grade leucine (Sigma-Aldrich Corp., St. Louis, MO) was added to the special 
media at a concentration of 450 mM (leucine enriched media, used as control) or 0 mM 
(Leucine deprived media). Once HepG2 cells were plated and starved overnight, cells were 
washed with 1X PBS and subsequently treated with either Leucine deprived media or Leucine 
enriched media (2 mL/well).  The cells were then stored in the incubator at 37°C in 20% O2 
and 5% CO hours at 37°C, in either normoxia or treated with hypoxia as listed in Section 2.5. 
2.5 Cell media and lysate preparation 
Following a 24-hour treatment period in the treatment-specific media, cells were removed from 
37°C incubator and placed on ice. The cell media was collected from each well into labelled 
tubes and placed in -20°C. The cells adhering to 6-well polystyrene culture plate were washed 
using 200 uL of ice cold 1X Phosphate Buffered Saline (Invitrogen, Carlsbad, CA) and 
subsequently treated with 150 uL of cell lysis buffer solution (1:1000 dilution of protease 
inhibitor cocktail, 1:1000 dilution of phosphatase inhibitor  cocktail 2, 1:1000 dilution of 
phosphatase inhibitor cocktail 3 and 1:100 dilution of cell lysis buffer stock, (Sigma Aldrich, 
St.Louis, MI)). The cells were subsequently scraped from the 6-well polystyrene culture plates 
using the cell lysis buffer solution and a plastic scraper (Diamed, Mississauga, ON) and stored 
into labelled tubes at -80°C overnight. The cell lysate samples were removed from -80°C the 
next day and sonicated for 15 secs, prior to being centrifuged at 13000 rpm, at 4 °C for 30 
mins. 
2.6 Bradford protein assay 
After sonication and centrifugation of the cell lysate sample, 3 uL of each sample was added 
to 42 uL double deionized water (ddH2O) to make a 1:15 dilution. Samples were plated in 10 
uL aliquots, in triplicates on 96-well Microplates (VWR). Additionally, protein standard 
samples with concentrations of 0, 25, 125, 250 and 500 ug/mL (ThermoFisher Scientific, 
Waltham, MA) were also plated on 10 uL aliquots, in duplicates. The protein standard samples 
and their relative absorbance values are used to create a graph of various concentrations (0, 25, 
125, 250 and 500 ug/mL), the concentrations of the unknown samples are correlated to be a 
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value within in that range based on the relative absorbance.  
A 200 uL aliquot of Bradford Reagent (BioRad) was added to each sample and standard using 
a multi-channel pipette prior to irradiation. The 96-well Microplates with protein samples and 
Bradford reagent was then placed on the Thermo Labsystems Multiskan Ascent Photometer 
(ThermoFisher Scientific) and irradiated with 595 nm light after an initial shake at 960 rpm. 
The relative absorbance resulting from the exposure was used to correlate the protein 
concentration in ug/uL  
𝑷𝒓𝒐𝒕𝒆𝒊𝒏	𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏	 ,
𝒖𝒈
𝒖𝑳0 = (𝟐𝟎	𝒖𝒈)/(
𝒂𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆
𝟏𝟎𝟎𝟎	𝒖𝑳 ) 
2.7 Cell viability assay 
Cells were grown and plated as described in section 2.1 in 96-well polystyrene plates. A total 
of 10 uL of the cell stock was added to each well and topped off with 10% FBS with 
DMEM/F12 to have a total of 100 ul of media per well. Cells were grown in 37 degrees Celsius 
incubator overnight and starved with 2% FBS or 0% FBS (depending on treatment specific 
starvation) for a minimum of 12 hours. The cells in the 96-well plate were rinsed with 100 uL 
1X PBS and treated as described in either sections 2.2, 2.3 or 2.4 for 24 hours. Following 
treatment, 10 uL of Dojindo Molecular Technologies Cell Counting Kit-8 (Washington, DC) 
was added to each well and left in incubator for one hour. After incubated plates were taken to 
Thermo Labsystems Multiskan Ascent Photometer (ThermoFisher Scientific) and irradiated 
with 495 nm of light. The relative absorbance values were recorded and normalized to wells 
containing only 2% FBS containing media for deduction of background light. The absorbance 
values for treatments were than normalized with control (cell treated with only 2% FBS) and 
graphically represented using GraphPad Prism via One-way analysis of variance with Dunnetts 
Multiple Comparison Post-Test. The values were graphically presented with a Standard Error 
of Mean (±SEM) for each sample. Significance values were depicted via (*) p< 0.05, (**)p< 
0.003 and (***)p< 0.001. 
2.8 Western blotting 
Using SDS-PAGE, equal amounts of cell lysate (20 ug) from treatments were loaded to 
determine the level of protein phosphorylation, total protein and action expression of mTOR, 
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AAR and AMPK functional readouts. All antibodies for mTOR and AAR functional readouts 
were purchased from Cell Signaling Technologies (Danvers, MA). All antibodies for AMPK 
functional readouts were purchased from Santacruz Biotechnology (Dallas, TX). Additional 
details regarding antibody dilution and preparation are included in the Supplemental Table 
1.1. The secretion of IGFBP1 in the HepG2 cell media as well as the phosphorylation sites 
Ser101, 119 and 169 were determined using 5 ul and 25 uL of cell media respectively. After 
samples were loaded and run in SDS-PAGE, the gel was transferred to a nitrocellulose 
membrane, which was washed twice with 1X Tris Buffered Saline (TBS) and blocked using 
5% skim milk or BSA in TBS with 0.1% Tween (TBST, BioShop) for 1 hr. After washing off 
the blocking buffer twice with TBS, antibodies prepared in 1:1000 dilution in TBST, 5% skim 
milk or BSA were applied to the nitrocellulose membrane and placed on a shaker at 4°C 
overnight. Following the antibody incubation, the membrane was washed twice with TBS and 
incubated with goat-anti-rabbit or goat-anti-mouse secondary antibody (BioShop, Burlington, 
ON) in 1:10000 ratio for 1 hour.  The membrane was washed twice with TBST before being 
visualized using ECL Clarity solution (BioRad, Hercules, CA), via chemiluminescence on the 
Molecular Imager VersaDoc (BioRad). All antibodies were purchased from cell signalling 
except for IGFBP1 (6303, Medix Biochemica, Espoo, Finland) and IGFBP1 phosphosites 
(YenZym Antibodies, San Francisco, CA). Westernblot analysis of proteins that are 
phosphorylated are stripped and re-incubated in an antibody corresponding to the total protein 
of the phosphorylated protein. After imaging both the phosphorylated and total protein levels 
on the same blot, the blot is once again stripped and re-incubated in beta-actin to examine 
loading controls. 
2.9 Data analysis 
The intensity of the bands on the visualized blots where analyzed using Image Lab software 
(BioRad, Hercules, CA). The following band intensity values normalized to the control 
identified in the set. Additionally, for blots that were probed for phosphorylated, total and actin 
protein, band intensity values were normalized by taking the phosphorylated protein bands, 
dividing that by the total protein bands and further dividing that value by the actin protein 
bands.  
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𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒	𝑝ℎ𝑜𝑠𝑝ℎ𝑜 − 𝑝𝑟𝑜𝑡𝑒𝑖𝑛	𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 	
H	𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑟𝑦𝑙𝑎𝑡𝑒𝑑	𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑡𝑜𝑡𝑎𝑙	𝑝𝑟𝑜𝑡𝑒𝑖𝑛 	K
𝑎𝑐𝑡𝑖𝑛	𝑝𝑟𝑜𝑡𝑒𝑖𝑛  
Following normalization, statistical analysis and graphing were done using GraphPad Prism 
via One-way analysis of variance with Dunnetts Multiple Comparison Post-Test. The values 
were graphically presented with a Standard Error of Mean (±SEM) for each sample. 
Significance values were depicted via (*) p< 0.05, (***)p< 0.003 and (****)p< 0.0001. 
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3 Results 
3.1 Activation of AMPK leads to upregulation of IGFBP1 
secretion and phosphorylation in hypoxia 
The role of AMPK activation in hypoxia resulting in MTOR downregulation has been 
extensively studied in various human and mouse models.74 However in this study we attempt 
to understand the relationship that AMPK activation in hypoxia has on IGFBP1 
hyperphosphorylation at Ser101, Ser119 and 169. The increase of IGFBP1 phosphorylation at 
these sites has previously been correlated to sequestering IGF1 and subsequently IGF1R 
downregulation.18,19,27 In this section we investigate the larger impact AMPK phosphorylation 
has on IGFBP1 and on growth signaling pathways such as MTOR in hepatocytes which is a 
major important component of fetal growth. 
3.1.1 Hypoxia induces AMPK phosphorylation  
Currently, several AMPK studies strongly suggest that cellular stress such as hypoxia leads to 
greater AMPK phosphorylation at the Thr172 residue on the gamma subunit (Section 1.6). We 
confirmed these findings to be significant through immunoblot analysis (Section 2.8-2.9) using 
phospho-AMPKThr172 targeting antibodies, of cell lysate from hypoxia treated (Section 2.2) 
HepG2 cells. twenty-four-hour hypoxic treatment of the cells induced a 3 to 4-fold increase of 
AMPK phosphorylation at Thr172 (Figure 10A). We also determined that, though levels of 
REDD1 protein increase 2 to 3-fold in hypoxic conditions in HepG2 cells, the increase is not 
detected to be significant (Figure 10B). Overall, the upregulation of AMPK phosphorylation 
in hypoxia was detected to highly significant and was chosen for further investigation in this 
study. 
Figure 10: Hypoxic conditions lead to upregulation of AMPK phosphorylation and levels of 
REDD1 protein in HepG2 cells. 
 
A-B. Representative western blots of AMPK protein at phosphorylation site Thr172 (Figure 
10A) and REDD1 protein levels (Figure 10B) from the cell lysate of hypoxia (H) treated and 
control (C) HepG2 cells (n=3 each) using equal aliquots of the cell lysate (20 ug). Hypoxic 
treatment of HepG2 cells increase AMPK phosphorylation and total REDD1 protein levels. 
Values are displayed as mean + SEM, NS p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 
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0.0001 versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; 
n=3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.2 Chemical induction of AMPK activation increases IGFBP1 
phosphorylation and secretion 
Next, we determined the effect of AMPK activation via AMPK chemical inducers AICAR and 
ASA (Section 1.6) on IGFBP1 secretion and phosphorylation at sites Ser101, 119 and 169. 
These sites are selected due to the availability of customized, targeted antibodies (Section 1.3, 
Figure 2) for IGFBP1 phosphorylation sites. We tested the effects of five different AICAR 
concentrations on HepG2 cells – 0.10, 0.25, 0.50, 0.75 and 1 mM (Figure 11) in normoxic 
conditions (Section 2.1). Total IGFBP-1 protein and phosphorylation levels were significantly 
increased at 0.25 mM AICAR (Figure 11). For ASA, we tested two different concentrations 
of 15.5 mM (3 ug/mL) and 25.8 mM (5 ug/mL) and found significantly optimal IGFBP1 total 
protein and phosphorylation levels to be at 15.5 mM (Figure 12) in normoxic conditions 
(Section 2.1). The level of total protein and phosphorylation of IGFBP1 at Ser101,119 and 169 
were detected using immunoblot analysis for both AMPK inducer treatments.  
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Figure 10. Hypoxia induces AMPK phosphorylation and REDD1 secretion in HepG2 cells. 
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Figure 11. Optimal levels of total and phosphorylated IGFBP1 protein found at 0.25 mM 
AICAR in dose response. 
A-D. Representative western blot of IGFBP-1 from the cell media of AICAR treated and non-
treated (control) HepG2 cells (n=3 each) using equal aliquots of the treated cell media. AICAR 
treatment of HepG2 cells increased IGFBP-1 secretion (Figure 11A) and phosphorylation at 
Ser101 (Figure 11B), Ser119 (Figure 11C), and Ser169 (Figure 11D). The most significant 
induction of IGFBP-1 secretion and phosphorylation are seen at 0.25 mM AICAR treatment. 
Values are displayed as mean + SEM. NS p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 
0 versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3.  
Figure 12. Optimal levels of total and phosphorylated IGFBP1 protein found at 15.5 mM 
ASA in dose response. 
A-D. A representative western blot of IGFBP-1 from the cell media of ASA treated and non-
treated (control) HepG2 cells (n=3 each) using equal aliquots of the treated cell media. ASA 
treatment of HepG2 cells resulted in increase of the levels of total IGFBP-1 (Figure 12A) and 
phosphorylated IGFBP-1 at Ser101 (Figure 12B), Ser119 (Figure 12C), and Ser169 (Figure 
12D) relative to control. The most significant induction of total and phosphorylated IGFBP-1 
levels are seen at 15.5 mM treatment of ASA. Values are displayed as mean + SEM. NS 
p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001 versus control; One-way analysis 
of variance; Dunnet’s Multiple Comparison Test; n=3. 
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Figure 11. Optimal levels of total and phosphorylated IGFBP1 protein found at 0.25 
mM AICAR in dose response. 
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Figure 12. Optimal levels of total and phosphorylated IGFBP1 protein found at 3 
ug/mL or 15.5 mM ASA in dose response. 
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3.1.3 Dorsomorphin treatment of HepG2 cells leads to decrease in 
IGFBP1 phosphorylation and secretion in normoxia 
After achieving effective activation of AMPK using AICAR and ASA, we wanted to 
investigate possible ways to inhibit AMPK and reverse hypoxic upregulation of IGFBP1. 
Inhibition of AMPK was attempted using a chemical inhibitor dorsomorphin (Section 1.6). 
Current literature has indicated Dorsomorphin as an effective inhibitor of cellular AMPK for 
short durations, however AMPK inhibition for longer incubation periods (24 hours) has yet to 
be tested. Additionally, Dorsomorphin in high concentrations can have and inhibitory effect 
on MTOR activity (discussed in further detail in Section 4.1.5), thus a dose response of 
Dorsomorphin is conducted in this section is to find a concentration that is low enough to not 
inhibit MTOR activity but high enough to actually suppress AMPK activity.  The effect of 
dorsomorphin mediated inhibition of AMPK on total and phosphorylated IGFBP1 protein 
levels were determined using immunoblot analysis (Section 2.8-2.9) of Dorsomorphin treated 
HepG2 cells. Five different concentrations of dorsomorphin were tested on HepG2 cells – 1.0, 
2.5, 4.0, 5.0, and 10 uM (Figure 13) in normoxic conditions (Section 2.1). The lowest levels 
of total and phosphorylated IGFBP-1 compared to control were found to be at 2.5 uM 
dorsomorphin (Figure 13). Although the effects of Dorsomorphin on AMPK inhibition are not 
clear, a decrease in IGFBP1 hyperphosphorylation can be seen as result of Dorsomorphin 
treatment of HepG2 cells. IGFBP1 phosphorylation at Ser101,119 and 169 were detected using 
immunoblot analysis for dorsomorphin and determined to be reduced compared to control by 
30-50%.  
Figure 13. Total and phosphorylated levels of IGFBP1 are significantly reduced in the 
dorsomorphin dose response. 
A-D. Representative western blot of total and phosphorylated IGFBP-1 from the cell media of 
dorsomorphin treated and non-treated (control) HepG2 cells (n=3 each) using equal aliquots 
of the treated cell media. Dorsomorphin treatment of HepG2 cells decreased levels of total 
IGFBP1(Figure 13A) and phosphorylated IGFBP-1 at Ser101 (Figure 13B), Ser119 (Figure 
13C), and Ser169 (Figure 13D). The most significant reduction of total and phosphorylated 
IGFBP-1 was seen at 2.5 uM dorsomorphin treatment. Values are displayed as mean + SEM. 
NS p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001 versus control; One-way 
analysis of variance; Dunnet’s Multiple Comparison Test; n=3.  
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Figure 13. Total and phosphorylated levels of IGFBP1 are significantly reduced using 
dorsomorphin mediated inhibition of AMPK in dorsomorphin dose response. 
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3.1.4 AMPK phosphorylation is upregulated via AICAR or ASA.  
Next, we determined the effect AICAR, ASA and Dorsomorphin has on AMPK activation via 
examination of the phosphorylation site at Thr172. AMPK is activated in AICAR (0.25 mM) 
or ASA (15.5 mM) treated HepG2 cells, leading to a 2-fold and 1.2-fold increase in AMPK 
phosphorylation at Thr172, respectively (Figure 14). The phosphorylation of AMPK at Thr172 
is not significantly decreased in dorsomorphin treated HepG2 cells (Figure 14). Additionally, 
treatment of HepG2 cells through AMPK activation via ASA (As) or AICAR (Ac) and 
inhibition via Dorsomorphin (Dm) has no significant effect on cell viability based on Cell 
Counting Kit -8 assay (Figure 15).  
Figure 14.  Activation of AMPK via ASA and AICAR increases AMPK phosphorylation at 
Thr172. 
A. Representative western immunoblots of AMPK phosphorylation at Thr172 (Figure 14) 
from the cell lysate of Dorsomorphin (Dm, 2.5 uM ), AICAR (Ac, 0.25 mM), ASA (As, 15.5 
mM) treated and non-treated (control) HepG2 cells (n=3 each) using equal aliquots of the cell 
lysate (20 ug). Inhibition of AMPK in HepG2 cells via Dorsomorphin decreased phospho-
AMPK 48-52% (Figure 14). While AMPK activation via ASA and AICAR increase phospho-
AMPK signaling 1.2-fold and 2-fold respectively. Values are displayed as mean + SEM. NS 
p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001 control; One-way analysis of 
variance; Dunnet’s Multiple Comparison Test; n=3.  
Figure 15.  Modulation of AMPK via dorsomorphin, ASA and AICAR with and without 
hypoxia (1% O2), has no significant effect on cell viability. 
A. Representative graphs of relative absorbance values of HepG2 cells treated with AICAR 
(Ac), ASA (As), Dorosomorphin (Dm) with and without hypoxia using CCK-8 assay at 450 
nm. Equal number HepG2 cells (3.5x105 cells/mL) were plated in each well. No significant 
changes in cell viability observed.  Values are displayed as mean + SEM. NS p³0.05, *p< 0.05, 
**p£ 0.01, ***p£ 0.001, ****p < 0.0001 control; One-way analysis of variance; Dunnet’s 
Multiple Comparison Test; n=3.  
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Figure 14. Activation of AMPK via ASA and AICAR increases AMPK phosphorylation at 
Thr172.  
 
 
Figure 15. AMPK inhibition and activation via dorsomorphin, ASA and AICAR 
with and without hypoxia has negligible effects on cell viability (CCK-8 assay). 
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3.1.5 AMPK activation via AICAR or ASA in hypoxia leads to levels of 
IGFBP1 phosphorylation similar to hypoxia alone 
After establishing a mode of chemical activation of AMPK, we examined the results of 
combining AMPK activation and hypoxia, to determine if the levels of IGFBP1 
hyperphosphorylation observed in hypoxia alone is similar to that of hypoxia with AMPK 
activation to suggest overlap of activity. We compared the levels of IGFBP1 phosphorylation 
resulting from AMPK activation via AICAR (0.25 mM) or ASA (15.5 mM) in normoxia (N) 
and hypoxia (H) with that resulting from hypoxia alone. We found that the greatest level of 
total (Figure 16A) and phosphorylated IGFBP1 at all sites (Ser101, 119, 160 – Figure 16B, C 
and D) resulted from AICAR treatment alone (Ac) compared to normoxia (control), hypoxia 
(H) or AICAR with hypoxia (HAc). A similar level of total and phosphorylated IGFBP1 
resulted from ASA treatment with (HAs) and without hypoxia (As) compared to hypoxia alone 
(H) at all IGFBP1 phosphorylation sites (Ser101, 119, 160). Both AICAR with hypoxia (HAc) 
and ASA with hypoxia (HAs) treatment resulted in similar levels of total and phosphorylated 
IGFBP1 at all sites (Ser101, 119, 160) in comparison to hypoxia alone.   
It is important to note however that the Ser101 (Figure 16C) site differed in that there was a 
significant difference was observed between AICAR and AICAR with hypoxia, defying the 
trend observed with the other sites. Although this is surprising, we have found in past studies 
as well that variations in the level of phosphorylation differ in response to different stimuli 
such as Rapamycin , hypoxia or leucine deprivation.18,19 In this specific case Ser101 site is 
highly sensitive to both AICAR and hypoxia, and combining the two stimuli does not have an 
additive effect but instead reduces the the Ser101 phosphorylation level to a lower amount. 
This is an interesting phenomenon we observe throughout this study for other combined 
conditions as well, where a combination treatment leads to reduced IGFBP1 signaling as 
opposed having an additive effect. This may be due to a threshold or optimal limit to the level 
of phosphorylation each IGFBP1 phosphorylation site can generate in response to stimuli. This 
is discussed in greater detail in Section 4.1.3 
Figure 16. HepG2 cells treated with AICAR alone resulted in the greatest amount of total and 
phosphorylated IGFBP1. 
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A-D. Representative western blots of total and phosphorylated (Ser101, 119, 160) IGFBP-1 
from the cell media of hypoxia (H) , AICAR (Ac, 0.25 mM), AICAR with hypoxia (HAc), 
ASA (As, 15.5 mM) and ASA with hypoxia (HAs) treated HepG2 cells alongside normoxia 
treated (N, used as control) HepG2 cells (n=3 each) using equal aliquots of the treated cell 
media. AICAR treatment of HepG2 cells increased total IGFBP-1 secretion (Figure 16A) and 
phosphorylation at Ser101 (Figure 16B), Ser119 (Figure 16C), and Ser169 (Figure 16D) 
drastically. However, AICAR with hypoxia treated cells resulted in IGFBP1 phosphorylation 
similar to hypoxia alone. Values are displayed as mean + Standard error of mean. NS p³0.05, 
*p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001 versus control; One-way analysis of 
variance; Dunnet’s Multiple Comparison Test; n=3.  
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 Figure 16. AICAR treatment with hypoxia results in IGFBP1 phosphorylation analogous to 
hypoxia alone at Ser 119 and 101 of IGFBP1. 
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3.1.6 AMPK activation in hypoxia leads to MTORC1/2 inhibition 
similar to hypoxic inhibition of MTORC1/2 
Following the examination of IGFBP1 levels as a result of AMPK activation in hypoxia, we 
investigated the affect AMPK activation has on MTORC1/2 activity, through the western blot 
analysis of MTOR functional readouts. We found that the greatest level of MTOR inhibition 
based on the levels of downstream functional readouts was seen in AICAR with hypoxia 
treatment. In the previous section we noted that AICAR with hypoxia lead to similar levels of 
IGFBP1 hyperphosphorylation as hypoxia alone but, here we are seeing a strong level of 
MTORC1 inhibition in the combined conditions. This may indicate the combined conditions 
have an additive inhibition on the MTOR pathway which does not necessarily correspond to 
high levels of IGFBP1 hyperphosphorylation. However, MTOR activity is a strong indicator 
for growth signaling activity, however in past studies we have seen that inhibition of this 
pathway does lead to significant increase in IGFBP1 hyperphosphorylation, the level of 
phosphorylation produced is not pronounced a those seen other stimuli such as amino acid 
deprivation.18,19 This indicates that observing IGFBP1 phosphorylation alone may not be 
sufficient to understand the underlying growth attenuation activity during cellular stress, 
instead, IGFBP1 hyperphosphorylation data must be taken in consideration with a profile of 
growth signaling proteins such as those found in the MTOR pathway.  
Activation of AMPK via hypoxia (1% O2) or AICAR (0.25 mM) or ASA (15.5 mM) 
attenuation of MTORC1 and MTORC2 downstream signaling. Both AICAR and ASA 
treatment of HepG2 cells reduces phosphorylation of Akt at Ser473 (Figure 17A), p70 S6k at 
Thr389 (Figure 17B) and 4E-BP1 at Thr70 (Figure 17C) in normoxic conditions as well as 
hypoxic. However, the greatest reduction of phosphorylation is seen in the levels of Akt 
phosphorylation (Figure 17C) in AICAR or ASA treated HepG2 cells with hypoxia compared 
to control (normoxia). No significant difference is seen between the levels of p70 S6k 
phosphorylation produced in response to hypoxia and hypoxia with AICAR or ASA. However, 
significantly lower levels of Akt and 4E-BP1 phosphorylation are seen in treatments of AICAR 
with hypoxia compared to hypoxia alone. The levels of Akt and 4E-BP1 phosphorylation seen 
in treatments of AICAR with hypoxia and ASA with hypoxia are similar when compared to 
each other. 
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Figure 17. MTORC1 and 2 inhibition via AICAR or ASA with hypoxia leads to greater 
attenuation of MTORC1/2 signaling than either treatments alone. 
A-C. Representative western blots of Akt at Ser473 (Figure 17A), p70 S6K at Thr389 (Figure 
17B), 4E-BP1 at Thr70 (Figure 17C) from the cell lysate of hypoxia (H) , AICAR (Ac, 0.25 
mM), AICAR with hypoxia(HAc), ASA (As, 15.5 mM) and ASA with hypoxia (HAs) treated 
HepG2 cells alongside normoxia treated (N, used as control) HepG2 cells (n=3 each) using 
equal aliquots of the cell lysate (20 ug). Treatment of HepG2 cells with hypoxia lead to 30-
40% decrease of phosphorylation of Akt and S6k, as well as 50% decrease of 4E-BP1 
phosphorylation. Treatment of HepG2 cells via AICAR and ASA reduce phosphorylation of 
Akt, p70 S6k and 4E-BP1 by at least 50% in normoxic and hypoxic conditions. However, Akt 
phosphorylation is inhibited far greater in treatments with both AICAR and hypoxia or ASA 
and hypoxia compared to hypoxia, AICAR or ASA alone. Phosphorylation of Akt in treatments 
of AICAR and ASA in normoxia resulted in 30-40% reduction compared to control. Values 
are displayed as mean + SEM. NS p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001 
versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. 
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Figure 17. MTORC1 and 2 inhibition via AICAR or ASA with hypoxia leads to greater 
attenuation of MTORC1/2 signaling than either treatments alone . 
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3.1.7 IGFBP1 hyperphosphorylation in hypoxia is unaffected by 
dorsomorphin treatment 
Next we determined if Dorsomorphin treatment is able to reduce IGFBP1 
hyperphosphorylation in hypoxia. The initial purpose of utilizing Dorsomorphin was to inhibit 
AMPK, however our previous results (Section 3.1.3) indicate that although Dorsomorphin 
treatment reduces IGFBP1 hyperphosphorylation, the effect of this compound on AMPK 
activity is unclear.  In this section, we found that treatment of HepG2 cells with Dorsomorphin 
in hypoxic conditions does not effectively reduce IGFBP1 hyperphosphorylation. Attempted 
inhibition of AMPK via Dorsomorphin (2.5 uM) leads to similar levels of total (Figure 18A) 
and phosphorylated IGFBP1 (Figure 18B-D) at all three sites (Ser101, 119, 169) in normoxia 
compared to untreated (control) HepG2 cells. As well, Dorsomorphin treatment of the cells 
lead to lower levels of total and phosphorylated IGFBP1 compared to hypoxia treatments. 
However, treatment of HepG2 cells with Dorsomorphin in hypoxia restored levels of total and 
phosphorylated IGFBP1 analogous to levels found in treatments of hypoxia alone. Thus, 
Dorsomorphin attempted inhibition of AMPK is ineffective in repressing hypoxia induced 
IGFBP1 secretion and hyperphosphorylation in HepG2 cells. 
Figure 18. Dorsomorphin treatment of HepG2 cells in hypoxia results in IGFBP1 hyper 
phosphorylation analogous to hypoxia alone. 
A-D. Representative western immunoblots of total and phosphorylated IGFBP-1 from the cell 
media of hypoxia (H) , Dorsomorphin (Dm, 2.5  uM), Dorsomorphin with hypoxia (HDm) 
treated HepG2 cells alongside normoxia treated (N, used as control)  HepG2 cells (n=3 each) 
using equal aliquots of the treated cell media. Dorsomorphin treatment of HepG2 cells 
stabilized IGFBP-1 secretion (Figure 18A) and phosphorylation at Ser101 (Figure 18B), 
Ser119 (Figure 18C), and Ser169 (Figure 18D) similar to levels found in untreated (control) 
cells. However, Dorsomorphin treatment with hypoxia resulted in IGFBP1 phosphorylation 
greater than hypoxia alone. Values are displayed as mean + Standard error of mean. NS p³0.05, 
*p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001 versus control; One-way analysis of 
variance; Dunnet’s Multiple Comparison Test; n=3.  
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 Figure 18. Dorsomorphin treatment of HepG2 cells in hypoxia results in IGFBP1 hyper 
phosphorylation analogous to hypoxia alone. 
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3.1.8 Dorsomorphin treatment of HepG2 cells in hypoxia does not 
rescue MTORC1/2 attenuation in hypoxia  
After observing the effect of dorsomorphin on IGFBP1 hyperphosphorylation, we investigated 
the effect dorsomorphin has on MTORC1/2 activity, through the evaluation of MTORC1/2 
downstream readouts. Inhibition of AMPK via Dorsomorphin (2.5 uM) in normoxia maintains 
MTORC1 (Figure 19A-B) and 2 (Figure 19C) downstream signaling levels similar to that of 
untreated HepG2 cells (control). However, Dorsomorphin with hypoxia (1% O2) leads to 
greater attenuation of both MTORC1 and 2 downstream signaling (phosphorylation of p70 S6k 
at Thr389, 4E-BP1 at Thr70, and Akt at Ser473) than hypoxia alone. This may suggest that 
Dorsomorphin behavior is affected by hypoxia or hypoxia mediates MTOR downregulation in 
ways independent of AMPK.  
Figure 19. Attempted AMPK inhibition via dorsomorphin with hypoxia leads to 
attenuation of MTORC1 and 2 signaling. 
A-C. Representative western blots of p70 S6K at Thr389 (Figure 19A), 4E-BP1 at Thr70 
(Figure 19B), Akt at Ser473  (Figure 19C) from the cell lysate of hypoxia (H) , Dorsomorphin 
(Dm, 2.5 uM), Dorsomorphin with hypoxia(HDm) treated HepG2 cells alongside normoxia 
treated (N, used as control)  HepG2 cells (n=3 each), using equal aliquots of the cell lysate (20 
ug). The treatment of HepG2 cells with hypoxia lead to 30-40% decrease of Akt and S6k 
phosphorylation and 50% decrease of 4E-BP1phosphorylation. The treatment of HepG2 cells 
with dorsomorphin lead to similar levels of Akt, p70 S6k and 4E-BP1 phosphorylation as 
control. However, the treatment of Dorsomorphin with hypoxia lead to 30% reduction of p70-
S6k and 4E-BP1 phosphorylation, as well as 60% decrease in Akt phosphorylation compared 
to control. Values are displayed as mean + SEM. NS p³0.05, *p< 0.05, **p£ 0.01, ***p£ 
0.001, ****p < 0.0001 versus control; One-way analysis of variance; Dunnet’s Multiple 
Comparison Test; n=3.  
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Figure 19. Attempted AMPK inhibition via dorsomorphin with hypoxia leads to 
attenuation of MTORC1 and 2 signaling. 
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3.2 IGFBP1 secretion and phosphorylation induction via 
combined hypoxia and leucine deprivation  
In the second part of this study, we investigated the effect of combining both hypoxia and 
leucine deprivation on IGFBP1 hyperphosphorylation. Previous studies have examined the 
impact of these stressors separately on HepG2 cells. However, in an effort to better understand 
the mechanisms of FGR, we will be combining these two stressors in order to better simulate 
conditions that fetuses afflicted with FGR would experience. In this portion of the study we 
look closely at both the levels of IGFBP1 hyperphosphorylation at all three sites, as well we 
investigate the MTOR and AAR pathway activity via western blot analysis of their downstream 
functional readouts. 
3.2.1 Combined treatment of hypoxia and leucine deprivation induces 
lower levels of IGFBP1 secretion and phosphorylation than 
leucine deprivation alone 
First, we examine the effect combined conditions of hypoxia and leucine deprivation have on 
total and phosphorylated IGFBP1 levels. HepG2 cells are treated with leucine enriched media 
(450 uM), leucine deprived media (0 uM), leucine enriched media (450 uM) with hypoxia (1% 
O2) and leucine deprived media (0 uM) with hypoxia (1% O2). The treatment of cells with 
leucine deprived media results in the greatest increase in total and phosphorylated (Ser101, 
119, 169) IGFBP1 levels (Figure20A-D). The treatment of leucine deprivation with hypoxia 
leads to increased levels of total (Figure 20A) and phosphorylated IGFBP1 (Figure 20B-D) 
significantly greater than untreated (control) HepG2 cells, but significantly less than the levels 
observed in leucine deprivation treatment alone.  The combined treatment of leucine 
deprivation with hypoxia was significantly greater than the leucine supplemented with hypoxia 
treated HepG2 cells at IGFBP1 phosphorylation sites Ser101 (Figure 20B) and 119 (Figure 
20C). However, the increase seen at Ser 169 (Figure 20D) and total IGFBP1 levels (Figure 
20A) between leucine deprivation with hypoxia and leucine supplemented with hypoxia are 
insignificant.  
Figure 20. Treatment of HepG2 cells with leucine deprivation with hypoxia (LH0) result in 
lower levels of IGFBP1 phosphorylation and secretion as leucine deprivation alone (L0). 
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A-D. Representative western blots of total and phosphorylated IGFBP-1 from the cell media 
of leucine 450 uM (control), leucine 0 uM, leucine 450 uM with hypoxia (1% O2) and 
leucine 0 uM with hypoxia (1% O2)  treated HepG2 cells (n=3 each) using equal aliquots of 
the treated cell media. Leucine 0 uM treatment leads 2-fold increase in total IGFBP1 (Figure 
20A), 5-fold increase in phosphorylation at Ser101 (Figure 20B), 23-fold increase of 
phosphorylation at Ser119 (Figure 20C) and 11-fold increase in phosphorylation at Ser169 
(Figure 20D). Leucine 0 uM with hypoxia treatment results in 5-fold increase in IGFBP1 
phosphorylation at Ser101, 17-fold at Ser119, 8-fold at Ser169 compared to untreated HepG2 
cells (control). Leucine 0 uM with hypoxia treatment lead to 1.5-fold increase in total 
IGFBP1 secretion compared to control.  Values are displayed as mean + SEM NS p³0.05, 
*p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001 versus control; One-way analysis of 
variance; Dunnet’s Multiple Comparison Test; n=3 
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Figure 20. Treatment of HepG2 cells with leucine deprivation with hypoxia (LH0) 
results in lower levels of IGFBP1 phosphorylation and secretion than leucine 
deprivation alone (L0). 
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3.2.2 Combined hypoxia and leucine deprivation treatment leads to 
MTORC1 and 2 inhibition similar to that of leucine deprivation 
alone 
Following the examination of IGFBP1 hyperphosphorylation levels as a result of combined 
treatments, we examine the effect the treatments have on MTORC1/2 activity through 
evaluation of their downstream functional readouts. HepG2 cells are treated with leucine 
enriched media (450 uM), leucine deprived media (0 uM), leucine enriched media (450 uM) 
with hypoxia (1% O2) and leucine deprived media (0 uM) with hypoxia (1% O2). Both the 
leucine deprivation (0 uM) treatment and leucine deprivation (0 uM) with hypoxia (1% O2) 
treatment lead to the significant decrease in phosphorylation of the MTORC1 downstream 
functional readouts p70-S6K at Thr389 (Figure 21A) and 4E-BP1 at Thr70 (Figure 21B). 
Only slight decreases in phosphorylation of MTORC2 functional readout Akt at Ser473 
(Figure 21C) is seen for leucine deprivation and leucine deprivation with hypoxia treatments. 
Leucine supplemented with hypoxia treatment lead to significant decrease in phosphorylation 
of p70-S6K at Thr389 (Figure 21A), 4E-BP1 at Thr70 (Figure 21B),  and Akt at Ser473 
(Figure 21C) as well, however the variation between leucine supplemented with hypoxia and 
leucine deprived with hypoxia is insignificant (Figure 21A-C).  
Figure 21. Leucine deprivation with hypoxia (LH0) treatment of HepG2 cells result in 
similar levels of MTORC1 downregulation at p70-S6K and p4EBP1 as leucine 
deprivation alone (L0) but not in MTORC2 downregulation (pAkt). 
A-C. Representative western blots of p70-S6K at Thr389 (Figure 21A), 4E-BP1 at Thr70 
(Figure 21B) and Akt  at Ser473 (Figure 21C) from leucine 450 uM (control), leucine 0 uM, 
leucine 450 uM with hypoxia and leucine 0 uM with hypoxia treated HepG2 cells (n=3 each) 
using equal aliquots of the treated cell lysate (20 ug). Leucine 0 uM treatment leads to a 50% 
of decrease p70-S6K at Thr389, 25% decrease in phosphorylation of 4E-BP1 at Thr70 and 
20% of Akt at Ser473. Leucine 450 uM with hypoxia lead to 28% decrease in p70-S6K 
phosphorylation at Thr389 (Figure 21A), 15% decrease in 4E-BP1 phosphorylation at Thr70 
(Figure 21B), and 26% decrease in Akt phosphorylation at Ser473 (Figure 21C). Leucine 0 
uM with hypoxia results in a 60% decrease in phosphorylation of p70-S6K at Thr389, 35% 
decrease in phosphorylation of 4E-BP1 at Thr70 and 30% of Akt at Ser473. Values are 
50 
 
displayed as mean + SEM. NS p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001 
versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Leucine deprivation with hypoxia (LH0) treatment of HepG2 cells result in similar 
levels of MTORC1 downregulation at p70-S6K and p4EBP1 as leucine deprivation alone (L0) 
but not in MTORC2 downregulation (pAkt). 
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3.2.3 Combined treatment of hypoxia and leucine deprivation leads to 
upregulation of AAR pathway 
We also examined the effect of hypoxia with leucine deprivation treatment of HepG2 cells has 
on AAR pathway by examining downstream functional readouts of AAR pathways using 
Western blot analysis. HepG2 cells are treated with leucine enriched media (450 uM), leucine 
deprived media (0 uM), leucine enriched media (450 uM) with hypoxia (1% O2) and leucine 
deprived media (0 uM) with hypoxia (1% O2). The treatment of cells with leucine deprived 
media and leucine deprived with hypoxia resulted in the greatest increase in phosphorylation 
of AAR pathway functional readouts GCN2 at Thr898 and EIF2a at Ser51. HepG2 cells treated 
with leucine deprivation with hypoxia lead to 5.5-fold increase in phosphorylation of GCN2 at 
Thr898 and 11-fold increase in phosphorylation of EIF2a at Ser51. The increase in GCN2 
phosphorylation seen in leucine deprivation with hypoxia treatment of HepG2 cells is much 
greater than the 4-fold increase in GCN2 phosphorylation seen in the leucine deprivation 
treatment alone or the 2-fold increase seen in leucine enriched media with hypoxia. The 
combined treatment also leads to EIF2A phosphorylation at Ser51 greater than that the 2-fold 
increase seen in the leucine deprivation treatment alone, as well as greater than the 10-fold 
increase seen in the leucine enriched media with hypoxia treatment. 
Figure 22. Treatment of HepG2 cells in leucine deprivation with hypoxia results in greater 
levels of GCN2 and EIF2A phosphorylation upregulation than either leucine deprivation or 
hypoxic treatments of HepG2 cells. 
A-B. Representative western blots of GCN2 (Figure 22A) at Thr898 and EIF2a at Ser51 
(Figure 22B) from the cell lysate of leucine 450 uM (control), leucine 0 uM, leucine 450 uM 
with hypoxia (1% O2)  and leucine 0 uM with hypoxia (1% O2)  treated HepG2 cells (n=3 
each) using equal aliquots. Leucine 0 uM treatment leads to 4-fold increase of 
phosphorylation of GCN2 at Thr898 and 2-fold increase in phosphorylation of EIF2a at 
Ser51. Leucine 0 uM with hypoxia leads to 5.5-fold increase of phosphorylation of GCN2 at 
Thr898 and 11-fold increase in phosphorylation of EIF2a at Ser51. Leucine enriched media 
with hypoxia leads to 2.5-fold increase in of phosphorylation of GCN2 at Thr898 and 2-fold 
increase in phosphorylation of EIF2a at Ser51. Values are displayed as mean + SEM. NS 
p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 0.0001versus control; One-way analysis 
of variance; Dunnet’s Multiple Comparison Test; n=3. 
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3.2.4 Combined treatment of hypoxia and leucine deprivation leads to 
minimal upregulation of ATF4 
Next we examined the effect of combined hypoxia and leucine deprivation on ATF4 – a protein 
indicated to be active in both the AAR and UPR pathway. Current literature suggests that 
conditions of hypoxia can elicit activation of ATF4 via the UPR pathway.62 However as 
previously discussed (Section 1.8), ATF4 activation can vary based on the type of stimulus 
that contributing toward ATF4 activation - namely hypoxia, leucine deprivation or amino acid 
deprivation. The treatment of cells with leucine deprived media (0 uM) resulted in the greatest 
increase of AAR pathway functional readout ATF4 both at 12 and 24 hours after application 
of treatment media. Interestingly, ATF4 levels decreased when treated with combined hypoxia 
and leucine deprivation. This may be due to the various upstream protein activators of ATF4 
that react to multiple stimuli, leading to a more subtle expression of total ATF4 levels but 
increased metabolic regulation through AAR, and UPR. This is discussed in further detail in 
Section 4.2.4.   
Figure 22. Treatment of HepG2 cells in leucine deprivation with hypoxia (LH0) 
results in greater levels of GCN2 and EIF2A phosphorylation upregulation than 
either leucine deprivation (L0) or hypoxic (LH450) treatments of HepG2 cells. 
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The ATF4 protein was detected via immunoblotting technique using equal amounts of cell 
lysate from treated HepG2 cells. The combination of leucine deprivation (0 uM) with hypoxia 
(1% O2) lead to 1.5-fold increase in ATF4 expression 12 hours after the beginning of the 
treatment. However, changes in ATF4 expression for leucine enriched (450 uM) with hypoxia 
and leucine deprivation (0 uM) with hypoxia was difficult to identify at 24 hours. However, a 
12-hour incubation period revealed leucine rich media (450 uM) with hypoxia to have a 2-fold 
increase in ATF4 expression and leucine deprived (0 uM) with hypoxia to have 1.5-fold 
increase in ATF4 expression.  Leucine deprivation (0 uM) alone produced 24-fold increase in 
ATF4 expression at 12 hours and 25-fold at 24 hours.  
Figure 23. Leucine deprivation with hypoxia (LH0) treatment of HepG2 cells results in 1.5-
fold increase in ATF4 expression, whereas leucine deprivation alone (L0) results in 24-25-
fold increase in ATF4 expression. 
 
A-B. Representative western blots of ATF4 at 12 (Figure 23A) and 24 hours (Figure 23B) 
after application of media from the cell lysate of leucine 450 uM (control), leucine 0 uM, 
leucine 450 uM with hypoxia and leucine 0 uM with hypoxia treated HepG2 cells (n=3 each) 
using equal aliquots. Leucine 0 uM treatment leads to 24-fold increase of ATF4 expression at 
12 hours and 25-fold increase at 24 hours. Leucine enriched with hypoxia leads to a 2-fold 
increase in ATF4 expression at 12 hours and 1.2-fold increase in ATF4 expression at 24 
hours after application of treatment media Leucine 0 uM with hypoxia lead to 1.5-fold 
increase of ATF4 expression at 12 hours and minimal change at 24 hours. Values are 
displayed as mean + SEM. NS p³0.05, *p< 0.05, **p£ 0.01, ***p£ 0.001, ****p < 
0.0001versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; 
n=3. 
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Figure 23. Leucine deprivation with hypoxia (LH0) treatment of HepG2 cells results in 
1.5-fold increase in ATF4 expression, whereas leucine deprivation (L0) alone results in 
24-25-fold increase in ATF4 expression. 
AAR Pathway is upregulated in combined hypoxia and leucine 
deprivation
49 kDa ATF4
42 kDa b actin
+ - + -
- - + +
Leucine (450 uM)
Hypoxia (1% pO2)
49 kDa ATF4
42 kDa b actin
+ - + -
- - + +
Leucine (450 uM)
Hypoxia (1% pO2)
12 hrs 24 hrs
21
L450 L0 LH450 LH0
0
1
2
3
4
15
20
25
30
R
el
at
iv
e 
to
ta
l A
TF
4 
le
ve
ls ****
NS
**
L450 L0 LH450 LH0
0
10
20
30
R
el
at
iv
e 
to
ta
l A
TF
4 
le
ve
ls ****
NS
**
(A)                                                                   (B) 
55 
 
4 Discussion 
4.1 IGFBP1 hyperphosphorylation via AMPK-mediated 
suppression of MTORC1 in hypoxia 
4.1.1 Summary of key findings in upstream regulation of MTORC1 
via AMPK 
In the first part of this study we investigated the possibility of AMPK mediated regulation of 
IGFBP1 secretion and phosphorylation. We hypothesized that activation of AMPK via AICAR 
or ASA would lead to increased total and phosphorylated IGFBP1 levels. We determined, 
through chemical activation and inhibition of AMPK in hypoxia, that though AMPK activation 
leads to increased levels of total and phosphorylated IGFBP1, inhibition of AMPK does not 
restore IGBP1 secretion and phosphorylation to normal levels in hypoxic conditions.  Our 
investigations also showed that AMPK is significantly activated and subsequently MTORC1 
downregulated (Figure 17A-C) in conditions of hypoxia alone. Additionally, hypoxia induces 
a wide range of nutrient sensing proteins, such as REDD1 (Figure 10B) to impede MTORC1 
activity and facilitate the hypoxia mediated stress response, however, the level of overall of 
REDD1 protein upregulation is not significant.  
Activation of AMPK using AICAR or Aspirin leads to increased IGFBP1 secretion and 
phosphorylation (Figure 16A-D), as well as downregulation in the phosphorylation of 
MTORC1 downstream functional readouts 4E-BP1 and p70-S6K (Figure 17A-B). This 
indicated that AMPK modulation alone can trigger IGFBP1 response (Figure 16A-D). When 
AMPK activation using AICAR or Aspirin was combined with hypoxia, minimal differences 
were seen in IGFBP1 secretion and phosphorylation between AMPK activation with hypoxia 
and hypoxia alone (Figure 16A-D). AMPK activation via AICAR showed the highest level of 
IGFBP1 secretion and phosphorylation, however AICAR treatment was combined with 
hypoxia, levels of IGFBP1 secretion and phosphorylation decreased. These findings indicate 
that there be a limited threshold to the level IGFBP1 upregulation that can be achieved through 
hypoxia, compared to the level of IGFBP1 upregulation achieved through the use of AMPK 
chemical inducers such as AICAR. However, interestingly, the downregulation of MTOR 
complexes were observed to be greater in AMPK activation with hypoxia than AMPK 
activation alone or hypoxia alone (Figure 17A-B). It is important to note that though MTOR 
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down-regulation is a key factor in IGFBP1 hyperphosphorylation, there are several nutrient 
sensing pathways such as AAR and UPR that may collectively contribute towards greater 
IGFBP1 hyperphosphorylation than MTOR downregulation alone.  Our studies have even 
previously indicated that upregulation of AAR (e.g. via leucine deprivation treatment)19 results 
in far greater IGFBP1 hyperphosphorylation than treatments that target MTOR downregulation 
(e.g. hypoxia or rapamycin)18. 
 Lastly, we observed that inhibition of AMPK via Dorsomorphin in hypoxia did not impede 
the increase in IGFBP1 phosphorylation and secretion observed during hypoxia (Figure 18A-
D). Similarly, Dorsomorphin mediated inhibition of AMPK in hypoxia was not able reverse 
the downregulation of MTORC1 activity as observed though phosphorylation levels of 4E-
BP1 and p70-S6K (Figure 19A-D). These findings indicated that although AMPK relays 
hypoxia signaling to induce MTORC1 down regulation and IGFBP1 phosphorylation, 
inactivation of AMPK alone does not impede hypoxia mediated signaling activity. Further 
investigation of the AMPK and REDD1 modulation of upstream MTOR activity is needed, 
specifically the upstream regulators of REDD1 such as Hif1a and LKB1 in future studies. 
4.1.2 In-vitro model of hypoxia 
In this study, conditions of fetal oxygen restriction were modeled in-vitro by placing HepG2 
cells with 1% O2 in a sealed chamber.13,75 Alternatively, healthy oxygen levels were modeled 
in-vitro by placing HepG2 cells with 20% O2 (normoxia) in a sealed chamber (Section 2.2). In 
addition to the several studies in current and past literature that use similar models of hypoxia, 
low oxygen tension in tissues has been shown to be a low as 3%.76,73 Fetal lambs with low 
oxygen tension have been shown to have O2 levels as low as 1-2% in the descending aorta, as 
opposed to normal oxygen levels which range from 4-12.1% (depending on the tissue type).77 
However, the model of healthy oxygen levels using 21% O2 may in fact be better described as 
hyperoxia, it is commonly used for most cell lines to produce optimal cell viability.31 In 
addition, previous studies in our lab have consistently modelled normoxic and hypoxic 
conditions using such O2 levels.18,19  
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4.1.3 Investigating methods of achieving optimal levels of total and 
phosphorylated IGFBP1 via chemical induction of AMPK  
In Section 3.1.2, we determined the optimal levels of AMPK activators AICAR and ASA 
needed in order to promote maximum increase in total and phosphorylated IGFBP1 without 
jeopardizing cell viability (Figure 15). Although, AMPK is activated in hypoxic conditions, 
our goal in activating AMPK was not to mimic hypoxia but to investigate the extent to which 
AMPK modulation can promote IGFBP1 increase and hyperphosphorylation. Identifying 
effective AMPK modulation can allow us to understand if AMPK modulation is a significant 
regulatory step in IGFBP1 regulation and subsequently attenuation of cell growth. Based on 
the data collected from treatment of HepG2 cells with AMPK activators in Figure 11-12, we 
determined that maximum levels of total and phosphorylated IGFBP1 can be achieved using 
0.25 mM of AICAR and 15.5 mM of ASA. Interestingly, we observed that each IGFBP1 
phosphorylation site differed in their level of phosphorylation in reaction to the various AMPK 
activators. Each IGFBP1 phosphorylation site is affected in a unique manner in response to 
various stimuli such as hypoxia, leucine deprivation or AMPK activation. This finding is 
something we have consistently seen in past studies in our lab as well, when investigating the 
effects of hypoxia18, leucine deprivation19 or rapamycin27 on IGFBP1 hyperphosphorylation.13 
Following the determination of optimal concentrations of AICAR and ASA, we investigated 
if those concentrations increase AMPK phosphorylation as well in Figure 14. We ensured that 
those concentrations were not lethal to cell viability in Figure 15. Cell viability remained 
relatively stable across all treatments using a CCK kit. Additionally, we examined the cell 
culture for signs of cell death based on qualitative observations of the cell media and cell 
growth throughout the treatment and study.  
Alongside AMPK activation, we also investigated AMPK inhibition in HepG2 cells using 
Dorsomorphin or Compound C in Section 3.1.3. We found that the use of dorsomorphin 
effectively reduced total and phosphorylated IGFBP1 levels at 2.5 µM in normal conditions 
(21% O2). We determined that Dorsomorphin effectively reduced AMPK phosphorylation 
without mitigating cell viability in Figure 14 and 15 respectively. However, Dorsomorphin 
was not effective in reducing levels of total and phosphorylated IGFBP1 in hypoxia (Figure 
13). We utilised the Dorsomorphin treatment of HepG2 cells as a quick and effective way to 
determine if AMPK inhibition alone can attenuate IGFBP1 signaling, however effective 
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inhibition can also be utilised using targeted small-interfering RNA (siRNA). We initiated the 
process of exploring effective AMPK silencing but were unable to observe successful silencing 
through commercially available siRNA in HepG2 cells. Effective silencing may however be 
achieved through highly targeted smart pool of siRNA in future studies. Regardless of the 
method of AMPK inhibition utilised, it is clear that AMPK inhibition alone cannot prevent 
IGFBP1 upregulation and hyperphosphorylation, as several proteins are involved in the 
upstream MTOR regulation of IGFBP1.  
4.1.4 Regulation of IGFBP1 hyperphosphorylation via AMPK 
mediated suppression of MTORC1 and MTORC2 in hypoxia 
We compared the levels of IGFBP1 upregulation and hyperphosphorylation that resulted from 
hypoxia to that from AMPK activation via AICAR or Aspirin, as well as both hypoxia and 
AMPK activation. We found that AMPK activation via AICAR or Aspirin (Section 3.1.2) 
mediates upregulation of IGFBP1 phosphorylation in hypoxia similar to hypoxia alone. 
However, AICAR treatment alone produced the greatest increase in IGFBP1 upregulation as 
well as hyperphosphorylation at all three sites (Ser101, 119 and 169). This is not surprising 
considering that we selected the dose of AICAR that produced the greatest levels of total and 
phosphorylated IGFBP1. As well AICAR is an endogenous cellular molecule that is produced 
as an intermediate during purine synthesis 47 as opposed to ASA or hypoxia (1% O2) which are 
chemical components not normally found in the cell. We believe this endogenous characteristic 
of AICAR allows the compound to be better accepted by the cells as opposed to ASA or 
hypoxia which in excess can be lethal, activating pathways that promote cell death.47 
Conditions of hypoxia and hypoxia with AICAR and  hypoxia with ASA lead to similar levels 
of IGFBP1 secretion and phosphorylation, with the exception of phosphorylation at Ser101. In 
past studies of IGFBP1 phosphorylation, it was noted that different treatments would lead to 
differentially activated phosphorylation sites and that not all sites were equally activated in 
response to same treatment, thus it is not unexpected for Ser101 to vary in phosphorylation 
compare to Ser119 and 169.18,19  
The fact that simultaneous exposure of hypoxia and AMPK activation leads to a lower levels 
of IGFBP1 phosphorylation and higher level of MTORC1 downregulation than hypoxia alone 
may suggest that AMPK activation has an important and highly regulated role in hypoxic 
signaling and that perhaps there is a threshold to AMPK activation during multiple cellular 
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stimuli. Another factor may be due to the fact that hypoxia is known to activate a number of 
stress responsive pathways such as the Unfolded Protein Response (UPR) pathway thus with 
the addition of AICAR may elicit an alternative multi-pathway reaction which may not 
necessarily have an impact on IGFBP1 phosphorylation but instead may restrict growth 
through other mechanisms. It is also interesting to note, that all three stimulators of AMPK 
(hypoxia, AICAR and Aspirin) lead to similar levels of MTOR downregulation despite AICAR 
resulting in much more IGFBP1 secretion and phosphorylation. It is possible that there is also 
a threshold to how much MTOR can be downregulated using multiple cellular stimuli before 
growth restriction leads to cell death. In our studies, we ensured that none of the levels of 
cellular stimuli, whether AMPK activators or hypoxia lead to the severity of cell death via cell 
viability assays.  Thus, upstream MTOR mediated upregulation of IGFBP1 may be more 
complex and may require greater investigation.    
4.1.5 Investigating methods of decreasing total and phosphorylated 
IGFBP1 via AMPK inhibition in hypoxia 
In order to further understand the role of AMPK in IGFBP1 regulation, we utilized AMPK 
inhibitor Dorsomorphin or Compound C (Figure 14). Inhibition of AMPK was used to 
determine if hypoxic downregulation of MTOR activity and upregulation IGFBP1 
phosphorylation and secretion could be prevented. Although there was no significant 
difference between untreated cells and Dorsomorphin treated cells in terms of MTOR activity 
(Figure 19A-C) and IGFBP1 secretion and phosphorylation (Figure 18A-D), Dorsomorphin 
was not able to rescue cells from the impact of hypoxic treatment. This is not surprising due to 
the fact that even with inhibition of AMPK, REDD1 expression along with various Hypoxia 
inducible factors (HIF) in response to hypoxia (Figure 10B) leads to increased TSC2 activation 
and subsequently inhibition of MTORC1. 
Inhibition of AMPK in hypoxia results in decreased IGFBP1 secretion and phosphorylation at 
Ser169 and Ser119. Modulation of AMPK Dorsomorphin did not interfere with cell 
proliferation and viability. Although Dorsomorphin is a potent inhibitor of AMPK (Figure 
14), dorsomorphin treatment does not reverse hypoxia induced MTORC1 downregulation and 
upregulation of IGFBP1 secretion and phosphorylation. MTORC1/2 activity is still sufficiently 
inhibited even with AMPK inhibition in hypoxia. This suggests that other proteins mediating 
hypoxic inhibition of MTOR such as REDD1 and HIF which converge on TSC2 activation, 
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may also be involved in IGFBP1 increase and hyperphosphorylation. Further investigations on 
the role of REDD1 and HIF in hypoxic inhibition of MTOR may provide a better understanding 
of upstream MTOR mediated regulation of IGFBP1. 
Additionally, we observed that high doses of Dorsomorphin treatment leads to greater IGFBP1 
phosphorylation (Figure 13A-D), the opposite of our intended use of the drug. We found that 
although dorsomorphin naturally promotes growth through AMPK inhibition, studies indicate 
that higher doses of the compound leads to downregulation of Akt, an important growth 
regulator.78 The downregulation of Akt by Dorsomorphin leads to downregulation of MTOR 
and its  functional activities and subsequently IGFBP1 upregulation (Figure 13A-D).  
Therefore, exceeding appropriate Dorsomorphin doses can prove to be detrimental to cell 
growth and proliferation.48 
 
Figure 24. Dorsomorphin mediated MTOR downregulation. Though inhibition of AMPK 
by Dorsomorphin/Compound C prohibits AMPK mediated MTOR downregulation, 
Dorsomorphin/Compound C can also directly attenuate MTOR signaling via Akt 
downregulation. 
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4.1.6 Error analysis for AMPK mediated increase of total and 
phosphorylated IGFBP1 
In this study, we indicated that hypoxic activation of AMPK and upregulation of REDD1 led 
to TSC2 mediated downregulation of MTORC1. However, there were two problems with this, 
first one being that REDD1 upregulation was not significant with our hypoxic incubation. Our 
methods of introducing hypoxia involve a 24-hour period in which HepG2 cells are exposed 
to 1% O2, it is possible the significant levels of increase are seen at an earlier time point, as 
various other studies have demonstrated that hypoxia significantly elucidates REDD1 increase 
at shorter time intervals.52 The second problem was that once AMPK is activated, AMPK 
phosphorylates TSC2 at Ser1387 and Thr1271, however when we attempted to show this 
through Western  blot analysis of the Ser1387 and Thr1271 site of TSC2 , we found that not 
only were the antibodies difficult to obtain commercially, but the commercially available 
antibodies were not able to properly detect the phosphorylation at those sites.79 This is was due 
to the fact that TSC2 has multiple phosphorylation sites that are activated by a wide range of 
proteins, AMPK targets 2 of those sites. TSC2 activation sites are sensitive to kinases that react 
to various cellular conditions and global health of the cell. As such the specific activation of 
Ser1387 and Thr1271 may occur transiently and thus difficult to characterize through 
immunoblotting methods. 44 Using MS-MS to target detection of phosphorylation is a possibly 
more effective yet expensive alternative to detection of TSC2 activation. 
Another area of concern was the degradation of Aspirin during cellular treatment. Aspirin or 
ASA is chemical that is foreign to human cells and as overtime is metabolized and excreted 
from the body.47 Interestingly, this occurs in the stomach and liver of humans. In this study we 
used human hepatoma cells, making Aspirin metabolism over time a concern. Regardless, 
Aspirin was able to significantly successfully induce IGFBP1 hyperphosphorylation and 
secretion, as well as MTOR downregulation (Figure 11A-D, 13A-D and Figure 16A-C). 
However, we observed that Aspirin was often not as effective as AICAR or hypoxia in IGFBP1 
induction or MTOR downregulation. In future studies, a time dependent examination of 
MTOR downregulation via Aspirin may help to better understand the full effects of the 
chemical prior to degradation. Additionally, in order to insure that all treatments resulted in 
viable cells, a cell viability test using a CCK-8 kit was done (Figure 15). The CCK-8 test 
indicated all treatments resulted in cell viability that was similar to the untreated HepG2 cells.  
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4.1.7 Conclusions and future directions for AMPK mediated 
upregulation of IGFBP1 hyperphosphorylation 
Previous studies have indicated the role of both AMPK and REDD1 in mediating TSC2 
upregulation in hypoxia during short intervals (1-2 hours).40,80 Current literature indicates that 
both AMPK and REDD1 relay hypoxic signaling via TSC2, while previous studies conducted 
in our lab indicate that TSC2 activation leads to MTOR downregulation in hypoxia - a crucial 
step in mediating IGFBP1 hyperphosphorylation.81 In this study our novel findings showed 
that, AMPK is an important instigator of IGBP1 hyperphosphorylation observed during 
hypoxia over a 24 hour period. The hypoxia mediated AMPK activation is shown to correlate 
to greater MTORC1 downregulation. However, further investigation needs to be done 
regarding the role of REDD1 and HIF proteins in modulating upstream MTOR regulation.  
While we explored the AMPK mode of TSC2 activation in this study, investigating the role of 
HIFs and REDD1 can provide a broader idea of the various pathways involved in the cellular 
stress response involved in growth attenuation. In future studies, TSC2 modulation via REDD1 
and HIF proteins maybe determined through echinomycin mediated activation of REDD1 and 
inhibition via PD184352 REDD1 inhibitor.81,82 As well, the effects of dual inhibition or 
activation of AMPK and REDD1 on TSC2 mediated MTORC1 downregulation and 
subsequently IGFBP1 hyperphosphorylation may be investigated. The dual inhibition of 
AMPK and REDD1 should be tested both in hypoxic and normoxic conditions, in order to 
determine their role in mediating hypoxia induced IGFBP1 hyperphosphorylation. Concurrent 
inhibition of AMPK and REDD1 in hypoxia, will help to determine if hypoxia induced 
IGFBP1 hyperphosphorylation can be prevented through these branches of TSC2 regulation. 
As well, concurrent activation of AMPK and REDD1 in normoxic conditions will allow us to 
determine if hypoxia-like IGFBP1 hyperphosphorylation can be stimulated through 
modulation of these proteins. In addition to chemical activation and inhibition, small 
interfering RNA (siRNA) mediated silencing of AMPK and REDD1 may also help to further 
examine and understand their role in IGFBP1 hyperphosphorylation and subsequently growth 
attenuation.  
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4.2 Determination of IGFBP1 hyperphosphorylation in 
combined conditions of hypoxia and leucine deprivation  
In the second part of this study we hypothesized that combined treatment of hypoxia and 
leucine deprivation in HepG2 cells would lead to synergistic downregulation of MTOR and 
upregulation of AAR pathway signaling, leading to greater levels of IGFBP1 
hyperphosphorylation than either treatment alone. However, through further investigation I 
observed that combined treatment of hypoxia and leucine deprivation lead to equal less 
IGFBP1 secretion and phosphorylation than either treatment at Ser101, Ser119 and Ser169 
(Figure 20A-D). Downregulation of MTOR activity in combined conditions was similar to 
hypoxia alone (Figure 21A-C). This was determined through examination of phosphorylation 
of MTOR downstream functional readouts p70-S6K, 4E-BP1 and Akt. Whereas upregulation 
of AAR in combined conditions was similar to Leucine deprivation alone (Figure 22A-B and 
Figure 23A-B). This was determined through evaluation of increased phosphorylation of AAR 
signaling proteins GCN2 and EIF2a. As well the total protein levels of AAR signaling protein 
ATF4 increased similarly in Leucine deprivation and Leucine deprivation with hypoxia. 
Overall the resulting IGFBP1 secretion and hyperphosphorylation was not synergistic as I had 
anticipated but rather maintained at an optimal threshold to promote growth attenuation. 
4.2.1 In-vitro model of nutrient deprivation  
In this study amino acid deprivation was modeled using leucine deprived cell media. Leucine 
is a branched chain amino acid (BCAA) and has been shown to be critical for fetal 
development.83 In cases of FGR/IUGR, lower levels of leucine seemed to be prevalent in 
addition to other branched amino acids. Analysis of placental nutrient transfer after 20 weeks 
of gestation indicate Leucine transfer to be particularly increased in human pregnancies. In 
addition, studies have also shown that Leucine and other BCAAs such as Phenylalanine are 
able to rapidly cross the placenta from mother to fetus. 4, 19,84 Past studies have indicated 
Leucine to play an important role in intercellular signaling. Leucine plays an important role in 
the synthesis of growth factors in the hepatocyte as well as hepatocellular regeneration. 4 
Additionally, the branched structure of leucine allows it to play an important role in maintain 
protein structure.85 Oral supplementation of leucine has been shown to be able to induce 
increased hepatic protein signaling, specifically in MTOR. Past studies in our lab have also 
indicated leucine depletion to have the most severe growth attenuation in HepG2 cells 
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compared to other BCAAs.13,19 For these reasons, we have also opted to use leucine deprivation 
for the stimulation of amino acid deprivation in this study. 
4.2.2 Reduced levels of total and phosphorylated IGFBP1 in 
combined conditions of hypoxia and leucine deprivation 
compared to leucine deprivation alone 
In our previous studies, we established that individual treatments of hypoxia, as well as leucine 
deprivation lead to upregulated levels IGFBP1 and hyperphosphorylation at Ser101, 119 and 
169.18,19 In this study, we found that, in side by side comparisons, leucine deprivation elicits a 
drastically stronger IGFBP1 response than hypoxia (Figure 20A-D). However, when we 
combined hypoxia and leucine deprivation, we found the resulting levels of IGFBP1 
upregulation and hyperphosphorylation to be higher than the levels observed in hypoxia but 
less than that observed in leucine deprivation. This contradicted our initial hypothesis in which 
we expected the combination of both treatments would to lead to greater IGFBP1 upregulation 
than either individual treatments. In fact, when we compare the IGFBP1 response from leucine 
deprivation treatment alone to the combined leucine deprivation with hypoxia, the latter seems 
to have a reduced IGFBP1 response. This may be due to the fact that hypoxia activates a 
number of pathways such as UPR that contribute to growth attenuation but do not necessarily 
lead to IGFBP1 hyperphosphorylation.66 The complex overlap and regulation of pathways that 
contribute to IGFBP1 phosphorylation are not fully understood. It is possible that there is a 
hypoxia induced hyperphosphorylation has a limit or threshold of IGFBP1 phosphorylation 
levels compared to the levels of IGFBP1 generated from leucine deprivation. Both current and 
previous studies have confirmed that IGFBP1 hyperphosphorylation is upregulated at different 
levels dependent on the cellular stress conditions (e.g. hypoxia, rapamycin, or leucine 
deprivation)18,19, however it is not clear, how cells differentiate between the IGFBP1 generated 
from hypoxia (via MTOR suppression) and that from leucine dep (AAR activation). Moreover, 
it is unclear how cells enforce restrictions or maintain IGFBP1 levels based on the type of 
stimuli (hypoxia, leucine deprivation or both). In the next few sections, we investigate the some 
of the biomolecular pathways mediating IGFBP1 via immunoblot analysis of MTOR and AAR 
signaling pathways. Further investigation of the overlap of additional network of pathways that 
relay hypoxic signaling, such as UPR may help us to understand exactly how hypoxic signaling 
in IGFBP1 regulation and growth restriction related mechanisms work (Section 4.2.4). 
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4.2.3 Investigation of MTORC1 and MTORC2 downregulation in 
hypoxia and leucine deprivation dual treatment  
When investigating MTOR downregulation, all three treatments (leucine deprivation, hypoxia, 
hypoxia with leucine deprivation) result in similar levels of 4E-BP1, p70-S6k and Akt 
phosphorylation. However, MTOR downregulation is small snapshot of one of many growth 
modulating pathways in play during cellular stress, it is possible stress signals are mediated 
globally throughout the cell. The fact that the addition of hypoxia to leucine deprivation 
treatment of HepG2 cells lowers the total and phosphorylated IGFBP1 levels compared to 
leucine deprivation alone indicates that the metabolic pathways responsible for sensing and 
relaying hypoxic conditions are far more complex than our current understanding of these 
pathways. Earlier in this study, we discussed Hypoxia Inducible Factors (HIFs) and their role 
in MTOR downregulation and IGFBP1 upregulation in response to hypoxia. However, it is 
important to note that though much of upstream MTOR regulation has yet to be fully 
understood, upstream MTOR regulators have been shown to interact with the Unfolded Protein 
Response (UPR) pathway. The UPR pathway, in addition to affecting upstream MTOR 
regulation, also reacts to hypoxia- activating a cascade of proteins (e.g. PERK, IRE1, ATF4), 
which may or may not lead to IGFBP1 upregulation. Thus, there are multiple metabolic 
responses to hypoxia in cells, of which only some have been identified in their role in 
promoting IGFBP1 hyperphosphorylation. Further investigation of the UPR pathway may help 
to improve our understanding of mechanisms that modulate IGFBP1 signaling.  
In addition to the complex array of metabolic pathways that respond to hypoxia, it is possible 
that there is a threshold or limit to the extent hypoxic conditions elicit IGFBP1 signaling. 
Perhaps there are specific regulatory factors in place within the cellular metabolic systems that 
help regulate hypoxic survival given that low oxygen conditions are something humans 
naturally experience, such as those living in high altitudes or experiencing in multiple 
gestations. For example, at a fundamental level we know that oxygen is required as an electron 
acceptor in cellular respiration  in the mitochondria to generate the energy (ATP) required to 
run cellular processes but we also know that in the absence of oxygen, anaerobic respiration 
can take place in the cytoplasm to generate ATP as well, although not as efficient.  Thus, even 
in low oxygen conditions, cellular processes can cope somewhat due to alternative mechanisms 
in place in order to generate the necessary energy. We are not introducing conditions 
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completely lacking oxygen (anoxia), just reduced oxygen (hypoxia). Conditions of anoxia can 
obviously be dangerous and lethal to the cell and thus avoided in our studies. 
4.2.4 Investigation of AAR pathway upregulation in hypoxia and 
leucine deprivation dual treatment  
Detection of AAR pathway signaling proteins phospho-EIF2a and phospho-GCN2 via 
immunoblot analysis in Figures 22-23 depicts a greater increase in phosphorylation of these 
proteins in conditions of leucine deprivation with hypoxia than individual treatments of either 
leucine deprivation or hypoxia. These findings in conjunction with immunoblot analysis of 
MTOR signaling proteins in Figure 21 indicates that combined conditions of leucine 
deprivation and hypoxia mediate a collective response through both MTOR and AAR pathway, 
despite the IGFBP1phorsphorylation levels being relatively lower in combined treatments 
compared with individual treatments. On possible explanation could be that though multiple 
cellular stress conditions may elicit moderate increases of IGFBP1 hyperphosphorylation, the 
array of biomolecular activity may still be incredibly diverse and active. The increase of 
IGFBP1 hyperphosphorylation is a strong indicator of growth attenuation but does not 
substitute as detailed purview of the complex metabolic activities taking place during nutrient 
stress; for understanding detailed molecular underpinnings of nutrient stress, an in-depth 
proteomic analysis of signaling proteins associated with various nutrient sensing pathways 
provides better insight.   
The detection of another AAR pathway signaling protein ATF4 through immunoblot analysis 
showed greater upregulation in the leucine deprivation only treatment but comparatively lower 
in the leucine deprivation and hypoxia treatment. This finding contrasts the trend observed 
with the other AAR pathway functional readouts, EIF2a and GCN2 which are most elevated 
in combined hypoxia and leucine deprivation treatment. Studies have indicated that the levels 
of ATF4 increase in response to EIF2a phosphorylation,86 however as previously discussed, 
EIF2a has several different kinases which react to different stimuli (shown in Figure 25 
below).61 The following downstream activity as a result of the EIF2a activation is uniquely 
dependent on the various protein kinases activating EIF2a. During Leucine deprivation and 
hypoxia, more than one of these kinases could have been activated, some of which resulted in 
ATF4 increase, others which may have resulted in increased translations of growth attenuating 
genes.87 
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Figure 25. Different kinases lead to EIF2a activation. Activation of EIF2a is mediated 
through four different kinases, each eliciting activation of unique set of genes. 87  
The findings in this study indicate that inhibition of MTOR and activation of AAR signaling 
in conditions of hypoxia and leucine deprivation occur independently of one another. However 
certain proteins such as ATF4 are affected by multiple nutrient sensing pathways (ie. AAR and 
UPR). Proteins that are cross implicated in multiple pathways require further investigation 
regarding their transcriptional activity and co-localization through experiments such as 
immunohistochemistry (IHC). The effect multiple pathways have on the activation of the 
nutrient responsive proteins in the growth signaling cascade is crucial to understanding the 
metabolic network mediating IGFBP1 hyperphosphorylation. Figure 26 depicts how proteins 
activated from both amino acid deprivation via AAR pathway and ER stress via UPR pathway 
converge on the activation of ATF4.30 Further investigations in the role of the UPR signaling 
pathway in modulating AAR signaling proteins as well as any other nutrient sensing pathways 
affecting IGFBP1 secretion and phosphorylation is needed to better understand the role of these 
metabolic markers.29 Systematic activation and inhibition of the UPR pathway proteins such 
as Protein Kinase R like ER kinase (PERK) could help evaluate the role of the UPR pathway 
in IGFBP1 hyperphosphorylation, as well as the larger interconnected network regulating 
growth attenuation in FGR.68 
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Figure 26. AAR and UPR pathway converge on EIF2a activation. Activation of EIF2a is 
mediated through AAR and UPR, each eliciting activation of unique set of genes.30 
4.2.5 Error analysis for hypoxia and leucine deprivation mediated 
increase of total and phosphorylated IGFBP1 
One problem we encountered in conducting immunoblot assays of the cell media proteins such 
as the total and phosphorylated IGFBP1, was the lack of a proper loading control. Several 
attempts were made to use fibrinogen as a loading control; however, fibrinogen levels are 
adversely affected in hypoxic conditions, making it an unreliable loading control for our 
experiments.88 Furthermore, we attempted ponceau staining, however since levels of proteins 
such as IGFBP1 are increased in response to hypoxia and growth indicating proteins such as 
fibrinogen or collagen are increased, ponceau staining does not offer insight into total quantity 
or protein being loaded independent of oxygen levels. Some studies have indicated the 
detection of cytochrome-c from the cell media as a viable loading control, which may be worth 
investigating in future studies.89 Future immunoblot assays could be followed up with cell 
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viability assays or cell counting assays to indicate the presence of a consistent number of cells 
in each replicate well. However, reagents applied to cell culture wells such as trypan blue can 
often interfere with detection of the IGFBP1 protein from the immunoblot membranes. A 
possible alternative may be to try the CCK-8 viability assay, which has been indicated by the 
manufacturers to have low interference in subsequent use in immunoassays. 
4.2.6 Conclusions and future directions for hypoxia and leucine 
deprivation mediated upregulation of IGFBP1 
hyperphosphorylation 
 Treatment of HepG2 cells with hypoxia and leucine deprivation leads to induction of IGFBP1 
phosphorylation analogous to individual conditions of either hypoxia or leucine deprivation at 
Ser101, however some reduced levels were seen at Ser169, Ser119 and total IGFBP1. The 
combined treatment leads to inhibition of MTOR signaling pathway at levels similar to hypoxia 
alone. However, the conditions of hypoxia and leucine deprivation lead to an upregulation of 
phosphorylation of the AAR signaling proteins EIF2a and GCN2 in combined conditions 
compared leucine deprivation alone. Activation of EIF2a is mediated through several different 
kinases such as PERK through the UPR pathway. Therefore, further investigation of the role 
of UPR pathway in mediating IGFBP1 hyperphosphorylation and growth attenuation is 
required.  
 One interesting aspect to note is that through-out this study, the addition of multiple cellular 
stressors such hypoxia with AMPK activation or hypoxia with nutrient deprivation, did not 
lead to an increased or additive effect on IGFBP1 levels compared to individual treatments. 
Increased levels of IGFBP1 protein and hyperphosphorylation may be a crucial aspect in 
signaling growth attenuation, but we showed that cells are able to effectively slow growth and 
proliferation (via detection of MTOR downregulation) with even 1-2-fold increases in 
IGFBP1. The metabolic sensitivity to IGFBP1 may be greater than that we anticipated during 
cellular stress. Further investigation of the overlap in cellular nutrient sensing pathways that 
lead to increased IGFBP1 hyperphosphorylation may help us to better understand the 
physiological changes in growth experienced in conditions of FGR. 
 
70 
 
4.3 Overall conclusions 
The goal of this study was to better understand the pathophysiology of FGR using HepG2 cells 
as model for fetal hepatocytes. We did this by examining the impact multiple cellular stressors 
can have on IGFBP1 hyperphosphorylation in addition to examining the proteins involved in 
relaying the cellular stress to IGFBP1 hyperphosphorylation. Previous studies using HepG2 
model have shown the effect hypoxia or nutrient deprivation has on IGFBP1 
hyperphosphorylation individually, however, in this study we combined both treatments to 
better simulate the multitude of conditions associated with FGR. We found that combined 
conditions led to the simultaneous modulation of nutrient sensing pathways associated with 
both hypoxia and nutrient deprivation. Combined cellular stress conditions led to lower levels 
of IGFBP1 hyperphosphorylation than nutrient deprivation alone but when compared to 
hypoxia, the level of hyperphosphorylation was the same or greater. This indicates that nutrient 
deprivation is a major modulator of total and phosphorylated IGFBP1 levels in HepG2 cells 
and that additionally, there is a threshold to the level of IGFBP1 hyperphosphorylation that 
occurs based on the type of cellular stress. Additionally, we examined the impact of direct 
modulation of hypoxia responsive protein AMPK has on the total and phosphorylated levels 
of IGFBP1 in HepG2 cells. Previous studies have indicated that AMPK activation in hypoxia 
is an important step in the attenuation of growth signaling activity, however a direct correlation 
between AMPK and IGFBP1 hyperphosphorylation had not been investigated. We found that 
chemical activation of AMPK leads to increased IGFBP1 phosphorylation, however inhibition 
of AMPK alone may not be enough to reverse the effects of hypoxia. This is due to the fact 
AMPK relays hypoxic signaling to growth signaling pathways alongside a network of other 
proteins that need to be equally investigated. Overall, this study attempts to shed light on both 
the cellular conditions and protein pathways that result in the metabolic changes seen in FGR. 
Understanding the mechanism of FGR disease may help to develop better prognosis and 
therapeutic treatments.  
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4.4 Supplemental Figures 
 
Supplemental Table 1.1. Antibody concentrations 
Antibody DTT 
Gel 
% 
Blocking 
(1xTBS) 
Primary 
antibody 
(1°) 
dilution  
1° dilution 
buffer 
(1xTBS) 
Secondary 
antibody (2°) 
2° dilution 
buffer 
(1xTBS) 
α IGFBP-1 
(6303) no 12% 5% BSA 1: 10,000 1 X TBS 
α mouse HRP 
1: 10,000 1X TBS 
Phospho 101-
IGFBP-1 yes 12% 
5% milk, 0.1% 
Tween 1:1000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
Phospho 169-
IGFBP-1 yes 12% 
5% milk, 0.1% 
Tween 1:1000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
Phospho 119-
IGFBP-2 yes 12% 
5% milk, 0.1% 
Tween 1:1000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
α actin ( Pan 
Actin) yes 10% 
5% milk, 0.1% 
Tween 1: 3,000 
5% BSA , 
0.1 % tween  
α mouse HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
α p70-S6K yes 8% 
5% milk, 0.1% 
Tween 1: 1,000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
α phospho  
p70-S6K yes 8% 
5% milk, 0.1% 
Tween 1: 1,000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
α Phospho 
4E-Bp-1 yes 15% 
5% milk, 0.1% 
Tween 1: 1,000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
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phospho 
AKT yes 10% 
5% milk, 0.1% 
Tween 1:1,000  
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
AKT yes 10% 
5% milk, 0.1% 
Tween 1:1,000  
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
pGCN2/total 
GCN2 yes 8% 
5% milk, 0.1% 
Tween 1:1000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
eIF2α/peIF2α yes 10% 
5% milk, 0.1% 
Tween 1:1000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
ATF4 yes 10% 
5% milk, 0.1% 
Tween 1:1000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
pAMPK yes 10% 
5% milk, 0.1% 
Tween 1:1000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
REDD1 yes 10% 
5% milk, 0.1% 
Tween 1:1000 
5% BSA , 
0.1 % tween  
α Rabbit HRP 
1: 10,000 
5% BSA, 
0.1 % tween  
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